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       INTRODUCTION 
INTRODUCTION 
         Hypothyroidism is a clinical syndrome resulting from a deficiency of thyroid 
hormones leading to generalized slowing down of metabolic processes. 
Hypothyroidism is most common hormonal deficiency, the diagnosis can be made 
quickly, confirmed or excluded and treatment is straight forward with excellent 
prognosis.  
Hypothyroidism can be  
(1) Primary (due to abnormality in thyroid gland itself),  
(2) Secondary hypothyroidism due to deficiency of TSH. 
 Incidence of hypothyroidism depends on different environmental and various 
geographic factors, they include dietary (iodine deficiency) and genetic variation in 
population. Iodine deficiency remains the main cause of hypothyroidism throughout 
the world, autoimmune disorder remains the other cause.  
The prevalence of primary hypothyroidism is 1:100 but it may be 5:100 if 
patients with subclinical hypothyroidism ( Normal T4, raised TSH) are included (0.5- 
2.0% in female and 0.2% in male).  
 
Thyroid hormone regulates the rate of metabolism, affects growth, modulate 
energy utilization  by increase in basal metabolic rate, increase oxygen consumption 
and facilitating heat production. Thus thyroid hormone has a role on functioning of all 
the cells. It has an important role in growth and development of kidneys 
 
The interplay between thyroid  and kidney in each other function is known for 
many years. Renal function is profoundly influenced by thyroid status by having 
(i) Pre renal effect – Influence of thyroid hormone on cardiovascular system 
and  renal blood flow  
(ii)Renal effect- Influence of thyroid hormone  on kidney structure, glomerular 
function (glomerular filtration rate), Tubular secretory and absorptive capacities 
through effect on  electrolyte pumps. Thyroid hormone has effect on renal 
concentrating and diluting capacity. 
Long standing hypothyroidism can cause significant reversible changes in renal 
function by alterations of  renal hemodynamics causing decrease in renal blood flow- 
decrease in renal plasma flow –decrease in glomerular filtration rate and single 
nephron GFR. Thus hypothyroidism is associated with many biochemical 
abnormalities including increase in serum uric acid and serum creatinine levels. Both 
uric acid levels and creatinine levels increase due to reduced GFR.  
Kuzell and colleagues in 1955 first suggested association between 
hypothyroidism and hyperuricemia. In 2001 Giordano et al showed the prevalence of 
Hyperuricemia in patients with hypothyroidism was high (33.3%) as compared to 
prevalence in general population ( 2-10%). 
 Mooraki A and Bastani B 1998  reported a case of  newly diagnosed 
hypothyroid patient with elevated serum creatinine level, hyperuricemia , reduced 
Creatinine clearance which improved with levothyroxine supplementation showing 
that these changes are because of deficiency of thyroid hormone and are reversible.  
So one of the important manifestations of hypothyroidism  but often 
overlooked one is impairment of renal function leading to many biochemical 
abnormalities like increased serum uric acid levels and serum creatinine levels. 
This study was designed for estimation and observation of changes in serum 
uric acid and serum creatinine levels and e GFR values in Hypothyroid patients. 
  
 
  
 
 
 
 
 
 
 
  AIM AND OBJECTIVES 
AIMS AND OBJECTIVES 
To estimate  serum uric acid and serum creatinine levels and calculate e GFR in 
hypothyroid patients (study group) and euthyroid controls (control group). 
1. To compare the serum uric acid levels among the study and control group. 
2. To compare the serum creatinine levels among the study and control group. 
3. To compare e GFR values among the study and control group. 
4. To find the correlation between Thyroid profile (T3,T4,TSH) and serum uric acid , 
serum creatinine and e GFR value in study group. 
5. To find the incidence of Hyperuricemia among study as compared to control 
group. 
 
 
 
 
  
 
 
 
 
 
 REVIEW OF 
LITERATURE 
REVIEW OF LITERATURE 
                                             HISTORICAL ASPECTS 
In 1656, it was believed in Western world that the major role of the thyroid 
gland was to lubricate the trachea GilmanAG et al. 
In females, the gland was assumed to have an ornamental purpose. 
Later in the same year, the anatomist Thomas Wharton identified the thyroid 
gland.  
In the year 1895, the action of thyroid gland on body metabolism was 
recognized by Magnus-Levy who identified the reduced basal metabolic rate in 
hypothyroid cases Berl Klin Wochenshr 1895.  
In 1926, the chemical structure of thyroid hormone, thyroxine was proposed by 
Harington. After a year, synthetic hormone was discovered. 
In 1909, Theodor Kocher a native of Switzerland was awarded the Nobel 
Prize for his work in Medicine on the “physiology, pathology and surgery of the 
thyroid gland" Nobel Foundation. Retrieved 2007-07-28.  
The earliest known description of uric acid dates from the year of the American 
Declaration of Independence, when German-Swedish chemist Karl Wilhelm Scheele 
(1742–1786) isolated a substance with acidic properties from a bladder stone, and 
named it ‘lithic acid’ (from Greek ‘lithos’, stone) . George Pearson (1751–1828) and 
Antoine Fourcroy (1755–1809) later changed the name from ‘lithic’ to ‘uric’, to 
reflect the presence of this substance in normal urine and its absence from some 
calculi. 
 
           URIC ACID SYNTHESIS 
 
 
 
 
URIC ACID 
INTRODUCTION 
Uric acid (2,6,8-trihydroxypurine, C5H4N4O3) is the end product of Purine 
metabolism. Human beings convert adenine and guanine  to Uric acid. In mammals 
other than higher primates, uricase converts uric acid to water soluble product 
allantoin. Since humans lack uricase, the end product of purine metabolism in 
humans is uric acid. 
PURINE SYNTHESIS 
Normal human tissues can synthesize purine and pyrimidine from amphibolic 
intermediates in quantities appropriate to meet physiologic demands. Ingested nucleic 
acids  and  nucleotides  undergo  degradation  in  intestinal  tract  resulting 
mononucleotides by nucleases, then converted to nucleoside and phosphoric acid. The 
nucleosides are split into constituent sugars and purine and pyrimidine bases and the 
bases are absorbed into circulation. Purine synthesized endogenously is used in 
synthesis of nucleic acids , ATP, NAD+, Co enzyme A etc. Very little of the purines 
derived from the exogenous pool (consumption of animal proteins ) is incorporated in 
nucleic acids. 
URIC ACID SYNTHESIS 
 Destruction of tissues lead to degradation of the nucleic acids leading to 
release of purines. So the purines derived from endogenous breakdown and from 
exogenous source of animal proteins undergoes degradation to form final product Uric  
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acid, generated primarily in liver. Through salvage pathway some of the purine are 
reutilised to again form the nucleotides. Adenosine is converted into inosine, then into 
hypoxanthine  then to xanthine which is converted to uric acid by xanthine oxidase 
which is molybdenum metalloenzyme that can be inhibited pharmacologically by 
drugs like allopurinol and febuxostat. Guanosine to guanine then to xanthine finally 
into uric acid. Other animals can convert uric acid into allantoin by means of uricase 
enzyme. 
    Uric acid is synthesized at a rate of 300mg daily. The total body pool of uric 
acid in male is 1200mg and in female  it is only 600mg. Urate production varies with 
the purine content of the diet and the rates of purine biosynthesis, degradation and 
salvage. Uric acid is a weak diprotic acid (has two dissociable protons) with pKa1≈5.4 
and pKa2≈10.3. At the physiologic pH of 7.4, a proton dissociates from ~99% of uric 
acid molecules, and thus most uric acid is present in the extracellular fluid as 
monovalent urate anion (also known as hydrogen urate or acid urate). Urates, the 
ionized forms of uric acid, predominate in plasma extracellular fluid and synovial 
fluid, as monosodium urate at pH 7.4. The divalent urate anion is practically non-
existent in the body because of the very high pKa2 and thus the term urate is generally 
used to refer to monovalent urate in the biomedical literature. Normal serum uric acid 
levels are 2.4-6.0 mg/dl in female and 3.4-7.0 mg/dl in male. 
  
Uric acid has an antioxidant property compensating for the antioxidant property 
of vitamin C (ascorbic acid) since it cannot be synthesized because of loss of enzyme 
L- gulonolactone oxidase (The Jekyll and Hyde of antioxidation). But  when the level  
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increases it has a pro oxidant activity (uric acid is redox agent). Higher levels of uric 
acid correlates with condition associated with increased oxidative stress like 
atherosclerosis, obesity, diabetes and metabolic syndrome. Some studies say that uric 
acid has a role in maintaining blood pressure (antinatriuretic effect and vascular 
effect). 
URIC ACID EXCRETION 
Uric acid is removed from body by two means -70% of uric acid is excreted by 
kidneys  and remaining  30 % secreted in intestine are acted upon by resident gut 
bacteria in a process termed intestinal uricolysis.  
Four-component model has been used to describe the renal handling of 
urate/uric acid:  
(1) Glomerular filtration,  
(2) Tubular reabsorption,  
(3) Secretion,  
(4) Post secretory reabsorption.  
Out of 100 %  Uric acid freely filtered at the glomerulus 99% of uric acid is 
reabsorbed at  S1 segment of proximal convoluted tubule. The reabsorption occurs 
through the transporters that exchange intracellular anions for uric acid, organic anion 
transporters (OAT) - urate transporter 1 (URAT1)  which is the major luminal 
pathway for urate reabsorption in humans, GLUT 9B- principal pathway of 
basolateral urate exit from proximal tubule cell in human kidney. 50 % of uric acid is 
secreted in S 2 segment of proximal convoluted tubule , 40% of this undergoes post 
secretory reabsorption  in more distal part of proximal convoluted tubule. 10% of 
filtered uric acid appears in urine. Totally urinary excretion of  uric acid is 10-12% of 
amount filtered. 
Thus  serum uric acid levels depend on 
1) Rate of purine synthesis 
2) Purine content of diet 
3) Degradation and salvage pathway 
4) Uric acid excretion 
 HYPERURICEMIA (INCREASED URIC ACID LEVELS) 
Hyperuricemia is defined by serum uric acid concentration greater than 7.0 
mg/dl in men or greater than 6.0 mg/dl in women. Hyperuricemia is caused by 
decreased renal excretion, increased production of  uric acid or increased dietary 
intake  of purines. Decreased renal excretion is involved in greater majority of cases 
of  Hyperuricemia and gout. 
CAUSES: 
Hyperuricemia  can be due to increased production of uric acid. It may  be 
primary due to certain enzyme abnormalities  or secondary 
1.PRIMARY  
a) HGPRT deficiency  results in Lesch nyhan syndrome-which is X linked disease 
resulting from deficiency of hypoxanthine guanine phosphoribosyl transferase, 
enzyme in biosynthesis of purines (lack of this enzyme prevents reutilization of purine 
bases in nucleotide salvage pathway) and results in increased de novo synthesis of 
purine nucleotides. 
b)In overactivity of PRPP synthase enzyme, abnormalities are less common 
2.SECONDARY  
a) Hemolytic anaemia , Megaloblastic anaemia 
b) Death of cancer cells leads to increased nucleic acid degradation, increased purine 
release and metabolism leading to increased uric acid levels.  
 (II) INCREASED  INTAKE 
This is not a major contributor  
1. Purine rich diet –sweet breads, meat 
2. Alcohol intake – increased lactic acid which inhibits secretion of uric acid 
(III) DECREASED URIC ACID EXCRETION 
Majority of cases of hyperuricemia are due to decreased uric acid excretion 
1.Renal disease of any cause resulting in impaired filtration and secretion 
2.Toxaemia of pregnancy 
3. Lactic acidosis- competition for binding site in renal tubule. 
4.Some drugs interfere with excretion of uric acid –diuretics (thiazides), salicylates 
(inhibit tubular secretion). 
MANIFESTATIONS: 
Nearly all uric acid is present as monosodium urate. At pH of plasma 7.4 ,urate 
is relatively insoluble and when the  concentration  exceeds 6.8mg/dl the plasma is 
saturated. As a result urate crystals may form and precipitate in tissues and results in 
renal  calculi formation . 
Increased uric acid levels results in gout which is characterised by deposition 
of monosodium urate crystals in joints, most commonly presenting with pain and 
swelling of great toe associated with renal calculi, urate nephropathy . 
Gout is primarily found in men of age 30-50 years. In women , urate 
concentration increases  after menopause. Postmenopausal women are more prone to 
develop hyperuricemia and gout. Treatment is use of allopurinol, febuxostat (both 
inhibit xanthine oxidase) which decrease the uric acid production and use of 
uricosuric drugs like Probenacid  which increase the excretion of uric acid and thereby 
decreasing serum uric acid levels. Acute episodes are treated by non steroidal anti-
inflammatory drugs (NSAIDS), colchicine, steroids. Acidity causes precipitation of 
uric acid to form calculi. It can be prevented by alkalinisation of urine and increased 
fluid intake. 
HYPOURICEMIA (LOW SERUM URIC ACID LEVELS) 
  Low level of serum uric acid  is less common. It may occur 
1. Secondary to severe liver disease 
2. Defective tubular reabsorption in proximal convoluted tubule as in Fanconi     
syndrome 
3.Chemotherapy with 6-mercaptopurine or azathioprine (inhibitors of de novo 
synthesis of purine bases) 
4.Overtreatment with allopurinol. 
CLINICAL USES: 
Serum uric acid level can be  used  
1.To confirm diagnosis and monitoring treatment of gout 
 2.To prevent urate nephropathy 
3.During chemotherapeutic treatment  
4.To assess inherited disorders of purine metabolism. 
5.To detect kidney dysfunction. 
6.Assist in diagnosis of renal calculi. 
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        CREATININE 
INTRODUCTION 
  Creatinine is formed in muscle from creatine phosphate by irreversible non 
enzymatic degradation and loss of phosphate . Creatine phosphate is the high energy 
buffer in skeletal muscle and brain. Creatinine phosphate prevents rapid depletion of 
ATP by providing a readily available high energy phosphate that can be used to 
regenerate ATP from ADP. 
CREATINE – SYNTHESIS AND  STORAGE 
Creatine is nitrogenous organic acid which is synthesized de novo in liver and 
kidney from glycine, arginine to form guanidinoacetate then with methionine forms 
creatine. Creatine can also be derived from dietary sources like meat and dairy 
products. Plants do not contain creatine so vegans depend on de novo synthesis. The 
efficient uptake of  dietary creatine requires continuous exercise or it is of little value. 
This creatine formed de novo or derived from dietary sources is then transported to 
muscle and brain , 95% of it is stored in skeletal muscle. In muscle, creatine is 
phosporylated (combines with ATP) to phosphocreatinine and stored . 
CREATINE PHOSPHATE –HIGH ENERGY RESERVE 
Creatine phosphate or phosphocreatinine is high energy reserve which acts as 
an energy buffer. Whenever there is an active muscle contraction, this gives 
continuous supply of ATP by getting converted to creatine and ATP. But when the 
muscle is relaxed and demand for ATP is not so great or when there is excess of ATP, 
Creatine is converted back to creatine phosphate by combining with the ATP. The  
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enzyme for this reaction is creatine kinase which is cytosolic isoenzyme present in 
myofibrils. 
CREATININE PRODUCTION 
Creatinine is formed from creatine and creatine phosphate in muscle and is 
excreted into plasma at constant rate related to the muscle mass. From creatine 
phosphate- loss of phosphoric acid and from creatine- loss of water molecule leads to 
formation of cyclic compound creatinine. This creatinine formed by irreversible 
nonenzymatic degradation diffuses into the plasma and is primarily excreted through 
urine. 2.6 % of phosphocreatinine reserves per day and 1.1% of creatine per day is 
converted to creatinine.  
Normal serum creatinine values for   
Adult male  is  0.8-1.4 mg/dl 
Adult female is  0.6-1.1 mg/dl 
 and in Children  value is proportional to body mass i.e., 0.2-1.0 mg/dl 
CREATININE EXCRETION 
Creatinine is released at relatively constant rate into the circulation, 
proportional to individual muscle mass, freely filtered from renal glomeruli and 
excreted in urine. Small amount are secreted by proximal tubule. Daily excretion is 
reasonably stable, thus serum creatinine is dependent on glomerular filtration rate. 
Plasma creatinine is inversely related to GFR. It is commonly used to assess renal 
filtration function and is considered highly a reliable indicator of renal health .Renal 
dysfunction diminishes ability to filter creatinine and serum creatinine rises in number 
of renal diseases. But serum creatinine level does not  raise until atleast half of 
kidney’s nephrons are destroyed or damaged.  
Thus the plasma creatinine concentration depends on 
1.Relative muscle mass 
2.Dietary intake  of non vegetarian diet 
2. Rate of creatinine turn over  
3.Renal excretion of creatinine 
INCREASED SERUM CREATININE LEVELS: 
1. Renal diseases due to any cause such as acute renal failure or chronic renal failure , 
chronic nephritis etc. 
2. Serum creatinine   also depends on renal  blood flow  -Decrease in renal blood flow 
is seen in congestive cardiac failure leading  to increased creatinine values 
3.Creatinine levels are proportional to muscle metabolism of body –Increased muscle 
mass (gigantism, acromegaly), Enhanced muscle metabolism(myasthenia gravis) lead 
to increased creatinine levels. 
Increased plasma creatinine levels roughly correlate with proportion of functional loss 
of nephrons 
 
SERUM CREATININE  LOSS OF NEPHRONS 
Normal     upto 29% 
>1.5 mg/dl     > 50% 
4.8-5.0 mg/dl     >75% 
10.0 mg/dl     90% 
4. Few drugs  like Probenacid, Cimetidine, Trimethoprine block tubular secretion  of 
creatinine and will increase serum creatinine levels even though they have not 
damaged the kidney. This is important in patients in whom GFR is already low. 
5. Raised creatinine is also seen in massive rhabdomyolysis and crush injury where so 
much creatinine is released into plasma even when glomeruli is working at their full 
capacity. 
6. Athletes taking oral creatine show slight increase in serum creatinine levels 
DECREASED CREATININE LEVELS 
1.Reduced muscle mass in elderly 
2. Small stature 
3.Although not a direct product of protein metabolism, inadequate dietary protein do 
influence the creatinine through slower muscle metabolism 
4.Muscle atrophy can also result in decreased creatinine levels 
 
     ESTIMATED GLOMERULAR FILTRATION RATE( e GFR) 
    (MDRD Equation) 
Glomerular filtration rate is defined as total quantity of filtrate formed in all the 
nephrons of both the kidneys per unit time. Normally it is 125ml /min or about 
180L/day. Measurement of GFR and renal blood flow is based on the principle of 
renal clearance. 
RENAL CLEARANCE 
Renal clearance of a substance is defined as the volume of plasma from which 
that substance is completely cleared per unit time. Therefore , clearance assesses an 
important aspect of kidney function as normally kidney is capable of clearing the 
substance from the plasma. 
Glomerular filtration rate (GFR) is equal to the clearance rate when any solute 
is freely filtered and is neither reabsorbed nor secreted by the kidneys. Clearance of a 
substance can be easily assessed by determining the concentration of the substance in 
plasma and urine, by estimating urine flow rate. The formula is as follows 
  CX=UX  x  V 
   PX 
CX – clearance of substance 
UX  - Urine concentration of substance in mg/dl 
   V - urine flow rate in ml/min 
PX - Plasma concentration of substance in mg/dl 
 
INULIN CLEARANCE TEST 
Criteria for the substance used for clearance test  
1.It should be freely filtered by the glomeruli 
2. It should be neither reabsorbed from nor secreted in the renal tubules 
3.It should not be synthesised or stored or altered in the kidney 
4. It should not be metabolised in the body 
5. It should be non toxic  
6. Its concentration in plasma and urine should be easily measured. 
 The substance usually used is Inulin ,a polymer of fructose, as it meets all the 
criteria of ideal substance for measuring GFR. 
It is injected intravenously initially as a bolus dose and then through the 
continuous infusion to maintain a constant concentration in the arterial plasma. 
Once  Inulin equilibrates with body fluids, urine and plasma sample are collected for 
estimation. 
CIN  = UIN  x  V 
      PIN 
 As Inulin is neither reabsorbed nor formed,  altered and stored in kidney, the 
filtered load of Inulin equals the rate of Inulin excretion. Therefore , Inulin clearance 
equals GFR 
  In early stage renal disease, the Inulin clearance may remain normal due 
to hyperfiltration in the remaining nephrons. Incomplete urine collection is an 
important source of error in Inulin clearance measurement. 
GFR can be accurately measured using radioactive substances, in 
particular  Chromium 51 and Technetium -99m. This helps to measure with only a 
few ml of urine or blood samples 
CREATININE CLEARANCE 
Endogenous creatinine clearance is used clinically to estimate GFR. Creatinine 
is end product of creatine phosphate , a skeletal muscle derivative. It is produced 
continuously from body and excreted continuously in urine. Therefore, concentration 
of creatinine in plasma and urine is normally stable .Its concentration are measured in 
plasma and urine and the urine flow rate is (volume of urine formed per unit time) 
determined. Then, creatinine clearance is calculated as: 
Ccreatinine   = Ucreatinine  x  V 
       Pcreatinine 
The advantages are that no infusion of creatinine is required. Creatinine is 
produced naturally by the body and is freely filtered by the glomerulus, but also 
actively secreted by peritubular capillaries in very small amounts such that creatinine 
clearance overestimates actual GFR by 10% to 20%. This margin of error is 
acceptable, considering the ease with which creatinine clearance is measured.  
Unlike precise GFR measurements involving constant infusions of Inulin, 
creatinine is already at a steady-state concentration in the blood and so measuring 
creatinine clearance is much less cumbersome.  But Creatinine clearance value varies 
with 
1. Age (Higher in young people) 
2.  Gender (male vs female)  
3. Race (black vs white)  
4. Muscle mass( higher in males compared to females) 
5. Increased dietary protein intake / malnutrition 
6. Pregnancy 
          Twenty four hour urine collection to assess creatinine clearance is no longer 
widely performed, due to difficulty in assuring complete specimen collection. 
There are many number of formulas deviced to estimate GFR or Creatinine clearance 
values on basis of serum creatinine levels assuming creatinine values in mg/dl 
ESTIMATED CREATININE CLEARANCE RATE (eCCr) using COCKCROFT-
GAULT formula 
A commonly used surrogate marker for estimate of creatinine clearance is the 
Cockcroft-Gault (CG) formula, which in turn estimates GFR in ml/min. It employs 
serum Creatinine measurements and a patient's weight to predict the creatinine 
clearance. The formula is  
 
Cr Cl (ml/min) =       (140-age in years) X body weight in kg 
         Serum creatinine(mg/dl) X 72  
Correction factors: (multiply by 0.85 if female)   
Estimated GFR 
The normal serum creatinine reference interval does not necessarily reflect a 
normal GFR for a patient because mild and moderate kidney injury is poorly inferred 
from creatinine alone. If reporting of  estimated GFR values done routinely, it can 
help the health care providers to detect chronic kidney disease resulting from 
hypertension, diabetes mellitus and in cases with family history of  renal disease . 
Assessment of  kidney function through e GFR is essential once albuminuria is 
discovered. The equation does not require weight or height variables because the 
results are reported normalized to 1.73 m
2
 body surface area. 
GFR value can be used in 
 Identifying the onset of renal insufficiency 
 To adjust the dose of drugs excreted by the kidney  
 To evaluate the effectiveness of therapy for progressive renal disease  
 To assess the progression of renal disease and detect the onset of end-stage 
renal disease 
(I) Estimated GFR (eGFR) using Modification of Diet in Renal Disease (MDRD) 
formula 
Levey et al in 1999 did a study to develop an equation from MDRD Study data that 
could improve the prediction of GFR from serum creatinine concentration. 
 The Modification of Diet in Renal Disease (MDRD) Study, a multicenter, 
controlled trial, evaluated the effect of dietary protein restriction and strict Blood 
pressure control on the progression of renal disease . During the baseline period, a 
Cross-sectional study of GFR, creatinine clearance, serum creatinine concentration 
and demographic and clinical characteristics in patients with chronic renal disease was 
done. 1628 patients enrolled in the baseline period of the Modification of Diet in 
Renal Disease (MDRD) Study, of whom 1070 were randomly selected as the training 
sample; the remaining 558 patients constituted the validation sample.  
The prediction equation was developed by stepwise regression -The following 
variables were considered for possible inclusion in the regression model: weight, 
height, sex, ethnicity, age, diagnosis of diabetes, serum creatinine concentration, 
serum urea nitrogen level, serum albumin level, serum phosphorus level, serum 
calcium level, mean arterial pressure. A p value less than 0.001 was used as the 
criterion for entry of a variable into the model. The cause of renal disease was not 
included. GFR is expressed in mL/min per 1.73 m
2  
body surface. 
The prediction equation was developed by stepwise regression applied to the 
training sample. The equation was then tested and compared with other prediction 
equations in the validation sample. The equation developed from the MDRD Study 
provided a more accurate estimate of GFR than measured creatinine clearance or other 
commonly used equations in practice. 
ADVANTAGES OF MDRD EQUATION 
1. It predicts GFR rather than creatinine and easy to use in clinical practice 
2.  It predicts GFR over a wide range of values  
3. It seems to be more accurate than the other equations tested and  does not 
require collection of a timed urine sample or measurement of height and weight 
4.  includes a term for ethnicity (chronic renal disease is more prevalent among 
black persons) 
5. It does not require knowledge of the cause of renal disease. 
6. The predicted GFR could be computed and reported by the clinical laboratory 
that receives the blood sample and patient demographic data. 
Thus Levey et al 1999 developed a new equation  to predict GFR that uses serum 
creatinine concentration, demographic characteristics (age, sex and ethnicity) and 
other serum measurements (urea nitrogen and albumin concentrations) more accurate 
than other widely used prediction equations. 
 The formula is ( 6 variable MDRD) 
 eGFR (ml/min/1.73m
2
) 
 =170 x [Pcr] 
-0.999
 x [Age] 
-0.176
 x [0.762 if female] x [1.180 if black] x [BUN] 
-0.170
 x 
[Alb]  
+0.318 
NEWER (4-variable MDRD)FORMULA 
Subsequently the formula was simplified to 4 variable version including only age, sex, 
ethnicity and serum creatinine values in 2006. The original MDRD used six variables 
with the additional variables being the blood urea nitrogen and albumin levels.The 
formula  known as "4-variable MDRD," which estimates GFR using four variables: 
serum creatinine, age, ethnicity and gender is as follows: 
 
 eGFR (ml/min/1.73m
2
) 
=186 x (S. Creatinine in mg/dl)
-1.154
 x (age in yrs) 
-0.203 
(0.742 if female) (1.210 if 
African American) 
Andrew S. Levey et al 2007 sought to reexpress the 4-variable MDRD Study 
equation for estimation of glomerular filtration rate (GFR) using serum creatinine 
(Scr) standardized to reference methods(Isotope dilution mass spectrometry IDMS). 
The IDMS-calibrated serum creatinine is about 6% lower then usual measurement, 
The reexpressed 4-variable MDRD Study equation for standardised Serum creatinine 
value (mg/dL) is 
eGFR (ml/min/1.73m
2)
 
=175 x ( Standardised serum Creatinine in mg/dl)
-1.154
 x (age in yrs) 
-0.203 
(0.742 if 
female) (1.210 if African American) 
Thus depending on whether  the laboratory has calibrated or not  its serum creatinine 
measurements to isotope dilution mass spectrometry (IDMS) MDRD equations are to 
be used accordingly. 
(II) Estimated GFR (eGFR) using the CKD-EPI formula 
The CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula 
was published in May 2009. Researchers pooled data from multiple studies to develop 
and validate this new equation. They used 10 studies that included 8254 participants, 
randomly using 2/3 of the data sets for development and the other 1/3 for internal 
validation. Sixteen additional studies, which included 3896 participants were used for 
external validation. 
Despite its overall superiority to the MDRD equation, the CKD-EPI equations 
performed poorly in certain populations including black women, the elderly and the 
obese and was less popular among clinicians than the MDRD estimate 
eGFR =141 x min(SCr/κ, 1)
α
 x max(SCr /κ, 1)
-1.209
 x 0.993
Age
 x 1.018 [if female] x 
1.159 [if Black] 
eGFR (estimated glomerular filtration rate) = mL/min/1.73 m
2
 
SCr (standardized serum creatinine) = mg/dL 
κ = 0.7 (females) or 0.9 (males) , α = -0.329 (females) or -0.411 (males) 
min = indicates the minimum of SCr/κ or 1  
max = indicates the maximum of SCr/κ or 1 
age = years 
(III) Estimated GFR (eGFR) using the Mayo Quadratic formula 
Another estimation tool to calculate GFR is the Mayo Quadratic formula. This 
formula was developed by Rule et al. in an attempt to better estimate GFR in patients 
with preserved kidney function. Studies in 2008 found that the Mayo Clinic Quadratic 
Equation compared moderately well with radionuclide GFR, but had inferior bias and 
accuracy than the MDRD equation in a clinical setting. 
 
(IV) Estimated GFR for children using Schwartz formula 
In children, Schwartz formula is used. This employs the serum creatinine (mg/dL), the 
child's height (cm) and a constant to estimate the glomerular filtration rate.  
e GFR  =     k x height(cm) 
      serum creatinine(mg/dl) 
where k is a constant that depends on muscle mass 
GFR -NORMAL VALUES 
    The normal range of GFR adjusted for body surface area measured by Inulin 
clearance is  
 In men  - 100mL/min/1.73m
2
 to 130 mL/min/1.73m
2
  
In women - 90 mL/min/1.73m
2
 to 120 ml/min/1.73m
2
  
 In children-  110 mL/min/1.73 m
2
 until 2 years of age and then it progressively 
decreases.  
As age advances beyond 40 GFR decreases progressively. 
STAGES OF CHRONIC KIDNEY DISEASE  
Risk factors for kidney disease include Diabetes, high Blood Pressure, family 
history, older age, ethnic group and smoking. For most patients, a GFR over 60 
mL/min/1.73m
2
 is adequate. But significant decline of the GFR from a previous test 
result can be an early indicator of kidney disease requiring medical intervention. The 
sooner kidney dysfunction is diagnosed and treated the greater odds of preserving 
remaining nephrons and preventing the need for dialysis. 
The severity of chronic kidney disease (CKD) is described by six stages 
 
STAGE 1-Normal kidney function – GFR above 90 mL/min/1.73 m2 and no 
proteinuria 
STAGE 2-CKD1 – GFR above 90 mL/min/1.73 m2 with evidence of kidney damage 
STAGE 3- CKD2 (mild) – GFR of 60 to 89 mL/min/1.73 m2 with evidence of kidney 
damage 
STAGE 4- CKD3 (moderate) – GFR of 30 to 59 mL/min/1.73 m2 
STAGE 5-CKD4 (severe) – GFR of 15 to 29 mL/min/1.73 m2 
STAGE 6- CKD5 kidney failure - GFR less than 15 mL/min/1.73 m
2 
 Some people add CKD5D for those stage 5 patients requiring dialysis; many patients 
in CKD5 are not yet on dialysis. Others add a "T" to patients who have had a 
transplant regardless of stage. 
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    THE THYROID GLAND 
INTRODUCTION 
             Thyroid is an important endocrine gland that primarily governs the rate at 
which metabolism occurs in individual cells. Thyroid gland produces two significant 
hormones - thyroxine and triiodothyronine by means of it, control the entire body 
metabolism. It develops from the floor of primitive pharynx during third week of 
gestation. Along with thyroglossal duct, it migrates from floor of tongue to the neck.  
The gland starts synthesizing thyroid hormones by 11weeks of intra uterine life.  
GROSS ANATOMY: 
The normal adult thyroid gland (Greek thyreos - shield, plus eidos - form), 
which weighs approximately 20 grams is a butterfly shaped, highly vascular organ and 
is soft in consistency. It is present on anterior aspect of the neck. It consists of 2 lobes 
that are connected by a band of tissue  known as isthmus. Four Parathyroid glands are 
located posteriorly at each pole of thyroid gland.Thyroid receives rich blood supply  
from superior and inferior thyroid arteries that originate from external carotid artery 
and subclavian artery respectively. Venous drainage is into external jugular  and 
innominate veins. Thyroid gland is innervated by autonomic nervous system.  
HISTOLOGY: 
Thyroid gland  includes 
1. Follicle – it is a spherical structure  and the functional unit of the thyroid gland. 
It has a lining made up of a single layer of follicular cells and is surrounded by 
a rich network of capillary blood supply.  
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               The apical side of the follicular epithelium faces the lumen of the follicle 
which is filled with a proteinacious secretory substance, colloid. This colloid is 
composed of thyroglobulin, a large glycoprotein molecule . 
               The size of the epithelial cells and the amount of colloid are dynamic 
features that change with activity of the gland . 
2. ‘C’ or Parafollicular cells - These are seen lying in between the follicles, they are 
derived from neural crest cells. Their main function is secretion of calcitonin.   
PHYSIOLOGY OF THYROID HORMONES  
The principal hormones synthesized and secreted by thyroid gland are namely 
1. T4  (3,5,3',5'-tetraiodothyronine  or Thyroxine)- 90% , is a prohormone 
2. T3   (3,5,3'-triiodothyronine)- 10% , this is active form 
3. rT3   (Reverse or 3,3',5'-triiodothyronine)- less than 1% ,the inert hormone 
4. Calcitonin                  
                  T3 ,T4, r T3 are secreted from thyroid follicles and calcitonin is secreted 
by parafollicular cells of thyroid gland. The thyroid  hormones are formed by the 
union of iodine and tyrosine residues. T4 is converted into T3 in peripheral blood and 
tissue and  r T3 is physiologically inactive. 
BIOSYNTHESIS AND SECRETION 
                Hormone synthesis occurs in the follicular cells of the thyroid gland and it 
requires two precursors  
a) Thyroglobulin containing tyrosine residues 
b) Iodide 
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  STEPS IN THE SYNTHESIS OF THYROID HORMONES: 
1. Thyroglobulin – synthesis and release: 
Thyroglobulin is a glycoprotein containing 123 tyrosine residues synthesised in 
endoplasimic reticulum of thyroid gland, packed in golgi apparatus and secreted into 
the colloid by exocytosis.  
2. Iodide Trapping 
             Iodide is obtained from dietary sources.  The iodides are transported from the 
vascular compartment into the colloid by a secondary active transport process. Na
+
 
and I
-
 are cotransported by Na
+
-I
-
symporter - NIS (sodium  iodide symporter) with 
the help of Na
+
K
+
-ATPase in the plasma membrane. Thus NIS cause 20 to 40 times 
intracellular iodine accumulation as compared to iodine concentration in plasma.This 
is known as iodide trapping.  Expression of the NIS gene is inhibited by iodide and 
stimulated by TSH.  
3. Oxidation of Iodide: 
             Iodide is oxidised to iodine. This iodine has the capability of binding with 
tyrosine mediated by an apical membrane peroxidase, enzyme.   
4.  Organification of thyroglobulin:  
               It includes iodination of tyrosine, a process in which iodine is incorporated 
into tyrosine residues within the glycoprotein, thyroglobulin. Thus the thyroglobulin 
which is being continually exocytosed into the follicular lumen gets iodinated to form 
both monoiodotyrosine (MIT) and diiodotyrosine (DIT) residues.  
 
 
5. Coupling: 
               After iodination, there is subsequent coupling through an ether linkage of 
two DIT molecules to yield T4 and one MIT molecule with one DIT molecule to form 
T3. The entire sequence of oxidation, iodination and coupling reactions are catalyzed 
by thyroid peroxidase (TPO), an enzyme complex that spans the apical membrane.  
STORAGE 
The thyroid hormones are stored in the follicular colloid for a period of about 3 
months. One thyroglobulin molecule has approximately 30 thyroxine and little 
triiodothyronine residues. 
RELEASE 
           It involves reabsorption of  a portion of colloid into the follicular cell across the 
apical surface. The lysosomal enzymes in the follicular cell digest peptide bonds 
between iodinated residues and thyroglobulin. This results in the formation of T4, T3, 
DIT, MIT in the cytoplasm . 
            There is iodothyrosine deiodinase enzyme specific for MIT and DIT which 
causes deiodination of mono and diiodotyrosines and cannot utilize T4 and T3 as 
substrates. The iodide is later reclaimed for the synthesis of thyroid hormones. 
Tyrosine residues from the degraded thyroglobulin are reused. 
TRANSPORT 
             In a normal adult, the thyroid gland secretes approximately 80µg of T4 and 6 
µg of T3 per day. About 80% of total production of T3 arises from peripheral 
deiodination of T4 and this occurs in peripheral organs primarily in liver and kidneys 
catalysed by a microsomal enzyme 5’-deiodinase.  
           Upon secretion, almost entire T4 and T3 are tightly bound to serum proteins like 
thyroid binding globulin (TBG), transthyretin and human serum albumin (HSA)..  A 
very minimal portion of the entire amount circulates as free form to enter cells and 
exert metabolic control. The binding proteins serve as a protected reservoir to 
prevent renal clearance.Thus prevents fluctuations in hormonal levels and conserves 
iodide. 
METABOLISM 
              The thyroid hormones are metabolized in the following ways. 
               1. De iodination – The thyroid hormones are deiodinated by the enzyme 
complex, deiodinases to form thyronines. Three types of deiodinases are present  
                2. Conjugation - In the liver, the thyroid hormones are metabolised by 
conjugation with sulphates and glucuronic acid. 
               3. Side chain modification – The alanine side chain of thyroid hormones 
may be modified to form acetic and pyruvic acid analogues. They have no 
physiological role. 
 
MECHANISM OF ACTION  
               The thyroid hormones execute their functions mainly by its genomic action – 
activation of nuclear transcription. This leads to enhanced functional activity of all the 
cells. The steps of mechanism of action are as follows 
1. T3 and T4 enter the target organs by carrier mediated transport  
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2. Inside cell, most of T4 is converted into T3, which binds with thyroid hormone 
receptors present in the nucleus.The thyroid receptor protein binds to thyroid hormone 
response elements (TRE) in the DNA via zinc fingers. 
3. Binding of T3 with thyroid hormone receptor-TRE elements cause translation of 
DNA that in turn increases transcription of  mRNA  
 4. Increased mRNA causes increased intracellular protein synthesis that stimulates 
cellular growth, maturation, increases intracellular enzyme synthesis, mitochondria 
formation, respiratory enzyme synthesis and increases Na+-K+ ATPase activity. 
5. Increased Na+-K+ ATPase activity increases cellular oxygen consumption, 
mitochondrial activity and increases general metabolism of the cell. 
BIOLOGICAL ACTIONS OF THYROID HORMONE 
1) EFFECTS ON GROWTH AND DEVELOPMENT 
 It has its effect on central nervous system by influencing axonal and dendritic 
development, myelination and intellectual development. 
 It has its effect on bone growth –maturation of growing epiphyseal plate and 
timely eruption of teeth. 
2) EFFECTS ON ENERGY METABOLISM 
 Thyroid hormone stimulates basal rate of metabolism, increases oxygen 
consumption and stimulates heat production. 
 Carbohydrate metabolism-Increase glucose absorption from GIT, Increased 
glycolysis  and gluconeogenesis. 
 Fat metabolism- Increases mobilisation of lipids, raises free fatty acids in 
plasma, decrease cholesterol, phospholipids and triglycerides. 
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3) EFFECTS ON ORGAN SYSTEMS 
 Regulates sympathetic nervous activity –by inducing synthesis of  β adrenergic 
receptors. 
 Maintains normal myocardial contractility – stimulates expression of the  most 
active isoenzyme form of myosin ATPase. 
 Maintains normal skeletal activity. 
REGULATION 
         Three possible regulatory mechanisms of thyroid hormones include 
 Hypothalamic- pituitary- thyroid axis 
 Autoregulation  
1. Hypothalamic- Pituitary- Thyroid --- HPT axis 
               Secretion of thyroid hormones is regulated by a feedback control 
mechanism. Hypothalamus secretes thyrotropin releasing hormone(TRH) which 
stimulates thyrotrophs of anterior pituitary to secrete thyroid stimulating hormone 
(TSH). TSH stimulates thyroid gland to secrete T3,T4. TRH and TSH are controlled 
by the negative feedback action of thyroid hormones. Thyroid hormone have an 
effect on hypothalamus to inhibit the secretion of TRH. 
Thus assessment of serum TSH level serves as an index regarding the functional 
capacity of thyroid gland.  
2. Autoregulation: 
                Autoregulation of the thyroid gland is done by iodide . If the intake exceeds 
it leads to inhibition of thyroxine synthesis. This autoregulatory phenomenon is 
known as the Wolff-Chaikoff effect. When iodide level falls, the production of 
thyroid hormone returns to normal. Thus constancy of the plasma concentration of 
thyroid hormones is maintained. 
HYPOTHYROIDISM 
Hypothyroidism defined as inadequate secretion of thyroid hormones. It may be  
primary or secondary according to cause. 
           a)Primary hypothyroidism - When hypothyroidism develops due to disease 
or causes that primarily affect thyroid gland. It is characterized by decreased thyroid 
hormones (T3,T4) and increased TSH in the serum. It is classified as  
 1)Goitrous hypothyroidism :  it may be because of Iodine deficiency or due to 
antibodies against thyroid peroxidise as in Hashimoto’s thyroiditis an autoimmune 
disorder, Drug induced (Lithium, Iodine), Dyshormonogenesis – defect in thyroid 
hormone synthesis.  
2)Subclinical hypothyroidism -  characterized by clinically euthyroid, normal T3,T4 
values but elevated levels of serum TSH. 
               b)Secondary hypothyroidism is characterized by atrophy of an inherently 
normal thyroid gland due to failure of TSH secretion in patients with hypothalamic or 
anterior pituitary disease. It may be pituitary hypothyroidism as in Sheehan’s 
syndrome (post partum necrosis of pituitary) or Hypothalamic hypothyroidism due to 
brain injury, tumours 
Clinical features of hypothyroidism: 
1. Fatigue , dry skin, cold intolerance, hair loss 
2.  Constipation, Weight gain 
3. Hoarseness of  voice,  Facial puffiness 
4. Menstrual disturbances  
5. Bradycardia , poor concentrating ability 
Diagnosis: 
                The gold standard test for screening hypothyroidism is the estimation of 
serum TSH. Further blood testing of T3 and T4 will diagnose the type of 
hypothyroidism. Anti-TPO antibodies should also be measured. 
Treatment: 
              Oral thyroxine (levothyroxine LT4) preparation (10-15 µg/kg/day) as a single 
daily dose on an empty stomach is used for the treatment of hypothyroidism. 
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EFFECTS OF THYROID HORMONES ON RENAL PHYSIOLOGY 
Thyroid hormones has its effect on renal function by two ways 
1. Prerenal ( prerenal insufficiency ) – effect on the cardiovascular system and the 
renal blood flow (RBF). 
2. The direct renal effect by influencing 
a. glomerular filtration rate (GFR), 
b. tubular secretory and reabsorptive processes 
 
(I)PRE-RENAL EFFECT OF THYROID HORMONE ACTIVITY ON    
 CARDIOVASCULAR SYSTEM 
INTRODUCTION 
Cardiovascular system consists of heart and blood vessels. Thyroxine has effect 
on heart by accelerating heart rate and force of contraction and causes vasodilation in 
blood vessels, decreases peripheral resistance and activates  RAAS (Renin angiotensin 
aldosterone system). Hypothyroidism causes decreased cardiac output , increased 
peripheral resistance and decreased blood volume leading to hypodynamic circulatory 
state thus further leading to  decreased renal blood and plasma flow. So normal 
secretion of thyroid hormone is essential to maintain normal cardiac output and the 
hemodynamics.  
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(I) CARDIAC MUSCLE (MYOCARDIUM)  
Heart muscle is striated muscle and has specialized areas known as intercalated discs 
which contain gap junctions allowing to act as functional syncytium.  
Whenever action potential is generated, it causes the myofibrils of muscle to 
contract.The action potential causes calcium ions to enter the cell through voltage-
dependent calcium channels in the membrane of the T tubule which then activates 
calcium release channels known as ryanodine receptor channels, in the sarcoplasmic 
reticulum membrane, triggering the release of calcium into the sarcoplasm. 
These calcium ions diffuse into the myofibrils to promote sliding of the actin 
and myosin filaments along one another and produce the muscle contraction. This 
process is known as excitation contraction coupling. 
At the end of the plateau of the cardiac action potential, the influx of calcium 
ions to the interior of the muscle fiber is suddenly cut off and calcium ions in the 
sarcoplasm are rapidly pumped back out of the muscle fibers into both the 
sarcoplasmic reticulum and the T tubule– extracellular fluid space. Transport of 
calcium back into the sarcoplasmic reticulum is achieved with the help of a calcium–
adenosine triphosphatase (ATPase) pump(SERCA). Calcium re-uptake is dependent 
on the action of Sarcoplasmic Reticulum Ca2+-ATPase [SERCA], which is 
normally inhibited by PLB (Phospholamban). Calcium ions are also removed from 
the cell by a sodium-calcium exchanger, the sodium that enters inside is transported 
out of the cell by the sodium-potassium ATPase pump. As a result, the contraction 
ceases until a new action potential comes along.  
EFFECT OF THYROID HORMONE ON MYOCARDIUM 
1.Thyroid hormone directly affects cardiac myocytes through its genomic action  by 
regulating genes important for myocardial contraction and electrochemical signalling  
 Increased expression of contractile proteins 
 Increased numbers of β-adrenergic receptors 
 Increased calcium release from sarcoplasmic reticulum 
 Increased sodium-potassium pump activity 
This  results in increase in cytosolic calcium which increases contractility .Thyroid 
hormone by positively regulating sarcoplasmic reticulum Ca2+ATPase(SERCA) and  
negatively regulating  phospholamban leads to  more rapid calcium reuptake thus  
enhancing diastolic relaxation.  
Thus the improved calcium reuptake during diastole apart from enhancing 
relaxation has a favourable effect on myocardial contractility. This is because when 
there is  greater end-diastolic reduction in cytoplasmic concentration of calcium there 
is increase in the magnitude of the systolic transient of calcium that, in turn, augments 
its availability for activation of tropomyosin units. 
Thus Myocardial contraction and relaxation,  mediated through the release and 
re-uptake of calcium respectively, is literally enhanced by thyroid hormone. 
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 (II) PERIPHERAL RESISTANCE (AFTERLOAD) 
 Periperal resistance  depends on two factors 
1. Vessel diameter 
2. Viscosity of blood  
Vessel diameter –vasoconstriction causes increased vascular resistance and decrease 
stroke volume. Stroke volume increases in vasodilation. Thyroid hormones induce 
important changes in the peripheral circulation. Vasculature is principal target for 
thyroid hormone. 
1. T3 has been shown to rapidly and directly cause relaxation of vascular smooth 
muscle cells, leading to decreased systemic vascular resistance. 
2. Generation of nitric oxide by endothelial cells is enhanced by thyroid hormones. 
nitric oxide (NO) is a lipophilic gas that is released from endothelial cells lining the 
blood vessels in response to a variety of chemical and physical stimuli, cause the 
blood vessels to relax. The increased NO release protects against excessive 
vasoconstriction.  
3. Tissue thermogenesis -Thyroid hormones increase metabolic rate and oxygen 
demands of the peripheral tissues resulting in locally mediated vasodilation.  
Thus all the three factors contribute to vasodilation and hence decrease in 
peripheral vascular resistance. 
 
   JUXTA GLOMERULAR APPARATUS 
 
 
  
 
 
(III) BLOOD VOLUME(PRELOAD) : 
Preload is the end diastolic volume and it depends on venous return , atrial 
pump activity and ventricular compliance.  
Thyroid hormone induces relaxation of blood vessel resulting  in  a reduction  in  
vascular resistance leading to decrease in blood pressure Renin angiotensin aldosterone 
system is activated in response to decrease in resistance  leading to  increased plasma 
volume through sodium retention. Thyroid hormone also stimulates erythropoietin secretion 
resulting in increased red blood cell mass. 
THE RENIN-ANGIOTENSIN ALDOSTERONE SYSTEM: 
RAAS is a hormone system involved in regulating arterial blood pressure. This 
system is activated by low blood volume (decreased BP). The decreased BP leads to 
decrease in filtrate flow rate.When plasma sodium concentration is reduced, it is 
sensed by juxtaglomerular cells (JG cells) of the kidneys and renin is released. Renin 
acts enzymatically on angiotensinogen to form angiotensin I which is converted to 
angiotensin II by angiotensin-converting enzyme, present in the endothelium of the 
lung vessels.  
Angiotensin II has two principal effects that can elevate arterial pressure.  
1.Vasoconstriction occurs intensely in the arterioles  and veins. Constriction of the 
arterioles increases the total peripheral resistance. Mild constriction of the veins 
promotes increased venous return of blood to the heart.  
2.The second principal means by which angiotensin II increases the arterial pressure is 
to decrease excretion of both salt and water by the kidneys.  
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HYPOTHYROIDISM AND CVS: 
1)Hypothyroidism compromises the function of cardiac muscle by  
 Systolic dysfunction occurs due to less active isoenzyme of myosin ATPase.  
 Diastolic relaxation is prolonged by reduction in SERCA activity.  
 Heart rate is reduced due to reduction in number of β1adrenergic receptors.  
 Decreased expression of contractile proteins, decreased sodium-potassium 
ATPase pump activity. 
 Cardiac function can be impaired further by fibrosis and accumulation of 
mucopolysaccharides in the myocardial interstitium.  
Bradycardia along with systolic and diastolic dysfunction leads to low cardiac 
performance. 
2)Thyroid hormone deficiency increases peripheral vascular resistance  
 Affects vascular smooth muscle tone and reactivity  
  Reduced  responsiveness to vasodilators  
 Decreased tissue thermogenesis 
 β receptor synthesis is impaired but α adrenergic activity predominate 
resulting in peripheral vasoconstriction and increased diastolic blood 
pressure. 
Thus increased systemic vascular resistance leads to impaired left ventricular diastolic 
filling. This leads to decreased preload subnormal cardiac output and reduced 
systemic perfusion. Cardiac output is reduced by 30-40% in hypothyroidism.  
Thyroid hormone has its influence on maturation of the renin-angiotensin  system  
(RAAS).  Plasma renin activity and plasma levels of angiotensinogen, angiotensin  II, 
aldosterone  are  directly  related  to  plasma levels of thyroid hormones. Hypothyroidism is  
associated  with  low  plasma  renin. 
Hypothyroidism leads to generalised  hypodynamic circulatory state. 
RENAL BLOOD FLOW : 
Blood flow to both kidneys is normally around 20-25% percent of the cardiac output  
1200-1300 ml/min. The Renal blood flow is reduced in hypothyroidism by  
 Decreased cardiac output (negative chronotropic and inotropic effects) 
 Increased peripheral vascular resistance 
 Intrarenal vasoconstriction  
 Reduced renal response to vasodilators  
 Reduced expression of renal vasodilators such as vascular endothelial growth 
factor (VEGF) and insulin like growth factor1(IGF1).  
In addition, pathologic changes in the glomerular structure in hypothyroidism, such as 
glomerular basement membrane thickening and mesangial matrix expansion may also 
contribute to reduced Renal blood flow. 
 
 
 
 
 
 
(II) RENAL EFFECT -THYROID HORMONE ACTIVITY ON KIDNEY 
A) EFFECTS ON RENAL GROWTH AND DEVELOPMENT 
Thyroid hormone  play an important role in growth and development of the kidney 
In Experimental animals, the availability of thyroid hormone affects the size, 
weight and structure of both kidneys during development .Thyroid hormone status 
affects the functioning renal mass (measured as the kidney to body mass ratio).  
Thyroid hormone is also important in the development of tubular function in 
both prenatal and postnatal periods by directly influencing the expression and activity 
of a number of ion channels and transporters. In experimental animals, thyroid 
hormone affects the maturation, activity and density of the Na+-Pi co transporter, 
increases Na+-H+ exchanger and Na+-K+-ATPase activity. Children with congenital 
hypothyroidism have a high incidence of congenital renal anomalies. These findings 
support an important role of thyroid hormone during early embryogenesis.  
B) EFFECT ON RENAL PHYSIOLOGY 
GLOMERULAR FILTRATION : 
The glomerular filtration is the first step in urine formation .This involves 
ultrafiltration of plasma that takes place through the glomerular filtering membrane 
which consists of glomerulus and bowmans capsule. The product of filtration is called 
filtrate that flows down the tubular lumen.The composition of the filtrate is altered as 
it passes through different segments of the tubule to finally become urine. As the rate 
of filtration is major determinant of tubular load, the final output from tubule depends 
on glomerular filtration. 
 
 GLOMERULAR FILTRATION 
 
 
 
 
 
MECHANISM OF GLOMERULAR FILTRATION: 
Glomerular filtration occurs through glomerulocapsular filtration barrier. This is 
governed by two major factors  
1. Pressure gradients or starling’s forces ( hydrostatic and osmotic gradients) 
across the glomerular capillary wall 
2. Filtration coefficient ( size of capillary bed and permeability of the capillaries) 
Glomerular filtration = Kf [(PGC-PT)-(IIGC-IIT)] 
Kf  -Filtration coefficient( the product of glomerular capillary wall permeability and 
effective filtration surface area)  
PGC – mean hydrostatic pressure in glomerular capillaries 
 PT –mean hydrostatic pressure in tubule 
 IIGC –glomerular oncotic capillary pressure 
 IIT – osmotic pressure of filtrate in the tubule 
Pressure gradients are due to operation of starling’s forces. The net filtration 
pressure across the glomerular membrane  depends on the difference between the 
hydrostatic pressure gradient and the glomerular capillary oncotic pressure (as osmotic 
pressure of tubular fluid is negligible). Thus the net filtration gradient is always from 
glomerular capillaries towards the tubule 
Filtration coefficient is product of glomerular capillary wall permeability and 
effective filtration surface area. Glomerular capillaries are about 50 times highly  
 STARLING FORCES 
 
 
 
 
 
 
 
permeable compared to capillaries in skeletal muscle. Filtration depends on size, 
shape, weight of the molecule and the electrostatic charge they carry. The surface area 
for filtration of the capillary bed depends on the size of mesangial cells. The 
contraction of mesangial cell decrease the area available for filtration and vice versa. 
Thus mesangial cell contraction impairs and relaxation facilitates GFR.  
GLOMERULAR FILTRATION RATE: 
  Glomerular filtration rate is defined as total quantity of filtrate formed in all the 
nephrons of both the kidneys per unit time , normally it is 125ml /min or about 
180L/day. The GFR is influenced by factors that alter renal blood flow , pressure 
gradients, glomerular capillary permeability and surface area for filtration. 
REGULATION OF GFR: 
The regulation of GFR  involves neural mechanisms , hormonal mechanisms, 
myogenic mechanism and tubuloglomerular feedback 
I )NEURAL REGULATION 
Both afferent and efferent arterioles are innervated by sympathetic fibers 
1.The sympathetic activity in renal nerve is less when the blood volume is normal.  
II) HORMONAL REGULATION 
Various hormones regulate GFR. This includes angiotensin II , dopamine, endothelin, 
nitric oxide, bradykinin, prostaglandins 
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III) AUTOREGULATORY MECHANISM   
The autoregulation of GFR maintains a constant rate of glomerular filtration despite 
change in systemic arterial pressure within the range of 80-180 mm Hg. This is mainly 
due to myogenic theory and theory of tubuloglomerular feedback. 
MYOGENIC THEORY: 
When arterial pressure increases, the afferent arteriole is stretched and stretch induced 
contraction of the smooth muscle of afferent arteriole decrease GFR. Opposite 
mechanism operates in hypotension. This mechanism contributes to the maintenance 
of a relatively constant renal blood flow and GFR because of the ability of individual 
blood vessels to resist stretching during increased arterial pressure, a phenomenon 
referred to as the myogenic mechanism.  
TUBULOGLOMERULAR FEEDBACK: 
 In each nephron , information from renal tubules (tubular fluid) is signalled to 
glomerulus of the same nephron by means of a special structure called  
juxtaglomerular apparatus. It consists of macula densa cells in the initial portion of the 
distal tubule and juxtaglomerular cells in the walls of the afferent and efferent 
arterioles. The macula densa is a specialized group of epithelial cells in the distal 
tubules that comes in close contact with the afferent and efferent arterioles 
The kidneys have a special feedback mechanism that links changes in sodium 
chloride concentration at the macula densa with the control of renal arteriolar 
resistance and autoregulation of GFR. This mechanism may actually cause changes in 
GFR in response to primary changes in renal tubular sodium chloride reabsorption  
Whenever there is elevated filtration at glomerulus or reduced absorption of 
sodium and water by proximal convoluted tubule, it causes tubular fluid at macula 
densa to have higher concentration of Nacl.  
Thus increased sodium is transported inside macula. It increases the cell 
osmolarity and adenosine released causes constriction afferent arterioles, dilation of 
efferent arterioles and inhibition of Renin release. This reduces both renal blood flow 
and glomerular filtration rate and is brought to near normal. Tubuloglomerular 
feedback can reduce GFR by 45%. 
When there is decrease in Glomerular filtration or decreased concentration of 
Nacl in tubular fluid at macula densa, increased reabsorption of sodium occurs at 
proximal convoluted tubule. There is release of prostaglandin E2 which acts on JG 
cells and stimulates renin release. Thus RAAS is activated which constricts efferent 
arterioles and dilates afferent arterioles. Thus increases  Glomerular filtration and its 
rate. 
Thyroid hormone have a hold upon tubular transport of sodium via their actions 
on the sodium–potassium ATP pump (Na/K ATPase) in the membrane of proximal 
tubules. 
HYPOTHYROIDISM AND KIDNEY 
Hypothyroidism is associated with  reduction in renal plasma flow  and GFR  
1.The functioning renal mass is reduced in hypothyroidism. There is a structural 
constraint imposed by limited glomerular surface area for filtration due to renal 
parenchymal growth retardation in hypothyroidism. 
3. The reduction in renal plasma flow is because of the indirect effect on CVS leading 
to generalised hypodynamic circulatory state and pathologic changes in the glomerular 
structure such as thickening of glomerular basement membrane and expansion of 
mesangial matrix leading to decrease in renal blood flow.  
4. The GFR is reversibly reduced (by about 40%) in more than 55% of adults with 
hypothyroidism due to several reasons.  
a) There is decreased sensitivity to β adrenergic stimulus  
b) Decreased expression and activity of a number of ion channels and transporters, 
mainly Na+-K+-ATPase. 
There is reduced sodium reabsorption in both proximal and distal tubular segments 
because of reduced activity of Na/K ATPase initially in the proximal tubules and later 
in almost all segments of the nephron. In addition, expression of renal basolateral 
chloride channel is reduced. Thus reduced sodium chloride reabsorption increases the 
distal sodium and chloride delivery, triggering the macula densa mediated 
tubuloglomerular feedback which reduces the RAAS activity. Consequently, the GFR 
falls. 
 
 
 
 
 
HYPOTHYROIDISM AND URIC ACID & CREATININE LEVELS 
Thus the changes in  renal hemodynamics in hypothyroidism  are decrement in 
renal blood flow, renal plasma flow, glomerular filtration rate (GFR)  and single 
nephron GFR.  
Karanikas and colleagues 2004 performed isotopic renal scans in 
thyroidectomised patients with severe hypothyroidism before and after thyroid 
hormone replacement. There was an increase in GFR with thyroid hormone 
replacement. In another study done by Villabona C and colleagues 1999 in 
hypothyroid patients, estimated renal plasma flow( 131I-hippuran clearance) and GFR 
(52Cr-EDTA clearance) is increased after thyroid hormone replacement  thus 
confirming that there is reduction in renal blood flow which is reversible by thyroid 
hormone replacement. 
Kuzell and colleagues (1955) examined 520 patient suffering from gout and 
found hypothyroidism in 20% of the males and in 30% of the females. Giordano et al 
(2003) study showed that hyperuricemia in hypothyroidism is associated with 
increased serum creatinine and decreased creatinine clearance. This fact suggests that 
hypothyroid hyperuricemia is secondary to a reduction in renal plasma flow and 
glomerular filtration leading to decrease in urate excretion. 
In hypothyroidism there is increase in serum creatinine due to   
 Decreased creatinine excretion because of decrease of  RBF & GFR, 
decrease in creatinine secretion( thyroid hormone plays a role) , 
 Increased creatinine production due to hypothyroid myopathy 
 
Den Hollander et al 2005  found that in hypothyroidism serum creatinine levels 
may go upto  6 mg/dl with few patients even having ESRD , although in most reports, 
creatinine levels have been in the range 1.5–2.5 mg/dl. Elevation of levels of serum 
creatinine can occur within as little as 2 weeks of significant hypothyroidism. These 
levels typically normalize rapidly with thyroid hormone replacement after short 
periods of hypothyroidism. 
Kreisman and Henessay et al (1999) observed  increased serum creatinine level 
associated with normal findings on urinalysis during acute, severe iatrogenic 
hypothyroidism in a patient  of thyroid carcinoma which returned back to normal level 
after the surgery , when a euthyroid state was achieved  by levothyroxine treatment. 
This led them to suspect hypothyroidism as the cause of elevated creatinine level, and 
prompted them to conduct an analysis of the patients treated in this manner to assess 
whether these changes were consistent or sporadic and if they were fully reversible. 
The consistency of the elevation in creatinine levels in this study argue against 
the previously held notion of a net unchanged creatinine value due to a balance 
between the decrease in renal clearance and a decrease in creatinine generation. This 
study confirms that the hypothyroid state is associated with a consistent elevation in 
the serum creatinine level presumably due to a decrease in the GFR and demonstrates 
that it is a reversible change that develops rapidly.  
Thyroid hormone has a role in maintaining normal skeletal muscle activity. 
Myopathy is very common among hyperthyroidism. It may occur in hypothyroidism  
also.
 
It sometimes manifests as muscle enlargement   in adults, this condition is called 
Hoffman syndrome.
 
In children with hypothyroid disease (cretinism), a pattern of 
proximal weakness and diffuse muscle enlargement  known as Kocher-Debr é -S é m 
é laigne syndrome can occur. Hypothyroid myopathy  can be associated  with an 
increased creatine kinase level and increased creatinine production. 
Mooraki A and Bastani B. 1998  explained the cause for increase in creatinine 
levels because of myopathy occurence in hypothyroidism leading  to increase in 
plasma CK and creatinine production.Thyroid hormone replacement therapy improves 
myopathy and renal function and reverses rhabdomyolysis. 
In a review article by Khan et al 2010 the serum creatinine concentration 
increases in hypothyroid patients due to reduction of glomerular filtration rate because 
of hemodynamic changes in severe hypothyroidism. Serum creatinine level may also 
be increased due to hypothyroid myopathy.  
 
  
 
 
MATERIALS AND    
 METHODS 
 MATERIALS AND METHODS 
PLACE OF STUDY 
 Study was conducted in the Department of Medicine, Department of 
Endocrinology, Government Rajaji Hospital in co-ordination with the Institute of 
Physiology, Madurai Medical College, Madurai for a period of one year. 
COLLABORATION DEPARTMENT 
 Department of Biochemistry, Madurai Medical College,  Madurai.  
ETHICAL COMMITTEE 
 Approval obtained from the ethical committee of Government Rajaji Hospital, 
Madurai. 
STUDY DESIGN 
 Prospective cross sectional study 
SAMPLE SIZE 
 Total  subjects        -  100  
Study population   -   50 
Controls                  -   50 
 
 STUDY POPULATION    
People  attending the outpatient department of Medicine and Endocrinology, 
Government  Rajaji Hospital / Madurai Medical College  
Inclusion Criteria: 
1. Newly detected cases of Hypothyroidism  
2.  Age - 21-45 years. 
3. Both male and female 
Exclusion criteria:  
1.Person on Thyroxine treatment . 
2. Pregnancy, Lactating mothers. 
3. Renal disease, Liver disease, Cardiovascular disease.    
4. Hypertension, Diabetes Mellitus 
5. Gout, Muscular disorders, Malignancy 
 6. Smoking , Alcoholism     
 7. Patients on drugs (Hypolipidemic drugs, Antihypertensives, steroids, probenacid,      
allopurinol etc.) 
 
    8. H/o chemotherapy or radiotherapy for malignancy 
CONTROL GROUP 
1. Age group -21-45 years 
2. Both male and female 
3. Having normal Thyroid profile 
 Thyroid profile –Normal range (Chemiluminescence Immunoassay -CLIA)  
T3     -  0.69 - 2.15 ng/ml  
T4     -  5.2 - 12.7 µg/dL  
TSH  -  0.3 - 5.5 µIU/ml 
MATERIALS USED FOR STUDY 
1. Proforma – to record the anthropometric measurements and the clinical findings of the 
subjects. 
2. Portable weighing  machine – to record  the  body weight  in  kilograms. 
3. Stadiometer – to   measure   the   standing   height   in centimeters. 
4. Standardized mercury sphygmomanometer – to record the Blood Pressure in mm of 
Hg. 
 
 METHODOLOGY: 
          The study was initiated with the approval of Institutional ethical committee, 
Madurai Medical College, Madurai and was carried out after explaining the procedures in 
detail and getting written informed consent from the subjects.  
The experimental protocol includes 
1) Recording of a detailed history including history of cardiovascular disease, 
diabetes mellitus, hypertension, surgery or any drug intake and family history of 
renal, muscular, liver disorders.   
2) Measurement  of  Anthropometric Indices:   
The subjects were asked to stand erect, with their arms relaxed at their side and 
feet together. 
 The following were measured: 
 Weight (in kilograms) was recorded using a portable standard weighing machine. 
 Height (in centimeters) was measured to the nearest 0.5 cm using a  stadiometer.  
 Body Mass Index (BMI) was calculated using Quetelet’s Index.                
        BMI =   Weight (Kg)/ Height (m2). 
1. Recording of vital signs viz. pulse rate, respiratory rate and measurement of 
blood pressure were done and documented. 
2. Blood investigations:  The investigations include 
1. Serum Uric acid. 
2. Serum Creatinine. 
 For venous blood collection, antecubital vein of front of forearm was selected. 
Skin was sterilized over the vein with a spirit cotton swab. And about 3 ml of blood was 
collected in a disposable syringe of 5ml capacity.  
            For separation of serum, blood taken in a glass tube was first allowed to clot at 
room temperature and then centrifuged. This separated serum was used to estimate serum 
Uric acid and Creatinine. 
 
ESTIMATION OF URIC ACID: 
Method: 
 Uricase –Trinder – Enzymatic and colorimetric method 
Principle: 
Uricase converts uric acid to allantoin and hydrogen peroxide. The hydrogen 
peroxide formed further reacts with 4 aminoantipyrine and TOOS by the catalytic action 
of peroxidase to form a quinoneimine dye complex. Intensity of the colour formed is 
directly proportional to the amount of uric acid present in the sample. 
 
Uricase 
Uric Acid +O2 + H2O Allantoin + H2O2 + H2O  
2H2O2+ 4 Aminoantipyrine  +TOOS   
 
Peroxidase 
Quinoneimine dye + 
 
  
 
 
 4 H2O  
   
 
 Reagent Composition: 
(Concentration and activity in test) 
Active ingredient Concentration  
Pipes buffer (p H -7.5) 50 m mol/L 
4- Aminoantipyrine 3 m mol/L 
Uricase ≥ 1500 U/L 
Peroxidase ≥ 2000 U/L 
TOOS 2 m mol/L 
 
Also contains non-reactive fillers and stabilizers. 
 
Uric Acid Standard: 
Uric acid Standard 6.0 mg/dl 
 
Reagent Preparation: 
The reagent is ready to use. Protect from bright light. 
Sample Type: 
Serum free from haemolysis. 
Sample Stability: 
Serum is stable for 7 days at 2
0
 to 8
0
C 
 
 
 Procedure: 
 Three tubes marked  as BLANK ,STANDARD , TEST  
o Working reagent( 1000 µL) is pipetted into three tubes marked 
 
o 25µL of distilled water is added to ‘BLANK’ tube 
 
o 25µL of standard is added to ‘ STANDARD’ tube 
 
o 25µL of sample is added to ‘TEST’ tube 
 
Pipette into tubes 
marked 
Blank Standard Test 
Working reagent 1000 µL 1000 µL 1000 µL 
Distilled water 25µL ---------- ----------- 
Standard  ------------ 25µL ------------- 
Sample  ----------- ------------ 25µL 
Mix and incubate for 5 minutes at 370 C. Read the absorbance 546/670 nm on 
bichromatic analyzers against reagent blank. 
Calculation: 
URIC ACID(mg/dl)  =  Absorbance of test   X Concentration of standard(mg/dl) 
        Absorbance of standard  
 
 
 
  
REFERENCE VALUES: 
Serum/plasma mg/dl 
Women 2.5-6.8 
Men 3.6-7.7 
 
ESTIMATION OF CREATININE: 
Method: 
 Modified Jaffe’s method ( Alkaline Picrate Method) 
Principle: 
Picric acid reacts with creatinine to form an orange coloured complex in an 
alkaline medium (creatinine reacts with the alkaline picrate). Intensity of the colour 
formed is directly proportional to the amount of creatinine present in the sample. 
 
Creatinine + Alkaline Picrate      Orange Coloured 
Complex 
 
Reagent Composition: 
Reagent 1 –picric acid reagent  
Reagent 2- buffer reagent 
 
 Creatinine Standard: 
Creatinine Standard 2.0 mg/dl 
 
Reagent Preparation: 
Equal volumes of reagent 1 and reagent 2 were mixed. Wait for 15 minutes before use. 
Sample Type: 
Serum free from haemolysis. 
Sample Stability: 
Serum is stable for 7 days at 2
0
 to 8
0
C 
Procedure: 
 Two tubes marked  as STANDARD , TEST  
o Working reagent( 1000 µL) is pipetted into two tubes marked 
 
o 100 µL of standard is added to ‘ STANDARD’ tube 
 
o 100 µL of sample is added to ‘TEST’ tube 
 
 
 
Pipette into tubes marked Standard Test 
Working reagent 1000 µL 1000 µL 
Standard  100 µL ------------- 
Sample  ------------ 100 µL 
 
 Mix well and read intial absorbance A1 , for standard and test after exactly 30 
seconds. Read another absorbance A2 of the standard  and test exactly 60 seconds later. 
Calculate the change in absorbance ΔA for both standard and test. 
ΔA = A2 - A1 
Calculation: 
Creatinine (mg/dl) =    ΔA of Test       × Concentration of standard (mg/dl) 
           ΔA of Standard 
REFERENCE VALUES: 
Serum/ Plasma               mg/dl 
Women  0.5– 1.1 
Men             0.6 -  1.2 
 
 
 
 
 
 
 CALCULATION OF ESTIMATED GFR (MDRD equation) 
eGFR (ml/min/1.73m2)  =186 x (S. Creatinine in mg/dl)-1.154 x (Age in yrs) -0.203 
Correction factors:  0.742 (if female); 1.212 (if African American)  
For Indian population, 
eGFR (ml/min/1.73m2) 
= 186 x (S. Creatinine in mg/dl)-1.154 x (Age in yrs) -0.203 (for female x 0.742) 
To determine e GFR value , the following data regarding the patient should be collected- 
1.Serum creatinine (mg/dl) 
2. Age (in years) 
3. Sex (M/F) - to use correction factor (0.742 if female) 
REFERENCE VALUES: 
In men  - 100mL/min/1.73m2 to 130 mL/min/1.73m2  
In women - 90 mL/min/1.73m2 to 120 ml/min/1.73m2  
 
 
  
 
 
 
 
 
 
RESULTS AND 
       OBSERVATION 
  
 
 
 
1.AGE DISTRIBUTION 
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 RESULTS AND OBSERVATION 
The serum uric acid levels and serum creatinine levels, e GFR values  in 
hypothyroid patients and euthyroid controls was analysed using unpaired student t test , 
correlation between thyroid profile (T3,T4,TSH) and serum uric acid , serum creatinine , 
e GFR value in hypothyroid patients were analysed using  Pearson’s correlation 
coefficient test and Prevalence of  Hyperuricemia among study group and control group, 
staging of e GFR among study group and control group is analysed by chi square test . By 
means of SPSS (Statistical Package for Social Sciences) software version 16, analysis 
of statistics was performed. The statistical significance was drawn at ‘p’ value < 0.05.  
1.AGE DISTRIBUTION 
AGE( in years) CASE CONTROL TOTAL 
 
21 – 30 15 30 45 
31 – 40 25 12 37 
41 – 45 10 8 18 
Total 50 50 100 
Mean 34.14  29.92    
Standard deviation 6.95 7.33  
p value 0.00396  Significant  
Table – 1 showing age distribution among cases and controls 
  
 
 
 
  
                                2. BMI DISTRIBUTION 
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 2.BODY MASS INDEX 
 
BMI (kg/m2) CASE CONTROL TOTAL 
 
≤20 4 2 6 
20.1 – 24.9 20 21 41 
25 – 29.9 17 21 38 
≥30 9 6 15 
Total 50 50 100 
Mean 25.49   25.32    
Standard deviation 4.34 3.77  
p value 0.417   Not 
significant 
 
Table – 2 showing BMI of study and control groups 
When comparing the BMI between cases and controls it was found that there was  
no statistical significance in the values between them. 
Results analysed using student T test showed a statistically insignificant ‘p’ value 
     
 
  
 
 
 
3.GENDER DISTRIBUTION 
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  3. GENDER DISTRIBUTION 
GENDER CASE CONTROL TOTAL 
 
MALE  5 4 9 
FEMALE 45 46 91 
TOTAL 50 50 100 
 
 
          Table – 3 showing gender distribution among study group and control group 
 
 
 
 
 
 
 
 
 
 
 
 4. THYROID DISTRIBUTION 
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 4.THYROID PROFILE (T3 , T4 ,TSH)   
 
Thyroid 
hormones 
CASE CONTROL p  value 
Mean Standard 
deviation 
Mean Standard 
deviation 
T3 
(ng/ml) 
0.854  0.377 1.5  0.35    <0.00001 (Significant) 
T4 
(µg/dL) 
6.42   3.14 9.57  1.84    <0.00001 (Significant) 
TSH 
(µIU/ml) 
32.02  16.6 2.25  1.04    <0.00001 (Significant) 
 
Table – 4 showing mean values of T3, T4 and TSH among study and control group 
When comparing the thyroid hormone levels between cases and controls it was 
found that there was statistical significance in the values between them. 
Results analysed using student T test showed a statistically significant ‘p’ value. 
 
 
 
 
  
 
 
 
5. URIC ACID 
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 5. SERUM URIC ACID ANALYSIS 
 
Name of 
the 
substance 
CASE CONTROL  
p value 
Mean Standard 
Deviation 
Mean Standard 
Deviation 
 
URIC 
ACID 
 (mg/dl) 
 
6.87   
 
1.16 
 
5.41  
 
1.07 
 
<0.00001      
Significant 
 
 
Table -5 showing mean value of uric acid 
When comparing the serum uric acid level between cases and controls it was 
found that there was a significant increase in the uric acid value in the study group than in 
the control group. 
Results analysed using student ‘t’ test disclosed a statistically significant ‘p’ 
value. 
 
 
  
6. CORRELATION OF  THYROID PROFILE AND URIC ACID IN     
                                     HYPOTHYROIDISM 
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6.CORRELATION BETWEEN THYROID PROFILE AND SERUM URIC ACID 
LEVELS IN HYPOTHYROID PATIENTS 
Thyroid 
hormones 
Serum uric acid (mg/dl) 
‘r’ value  
 
       ‘p’  value 
T3(ng/ml) - 0.079   0.585 (Not Significant) 
T4 (µg/dL) - 0.3915    0.004 (Significant) 
TSH (µIU/ml) 0.2505  0.079 (Not Significant) 
 
Table-8 showing correlation between thyroid profile and uric acid in hypothyroid patients  
When correlating between thyroid profile (T3,T4,TSH) and serum uric acid in 
hypothyroid patients , there was significant negative correlation between T4 and Uric 
acid, other two correlation between T3 and uric acid ,TSH and uric acid was weak and 
not statistically significant. Results were analysed using Pearson correlation 
coefficient test. 
 
 
 
 
  
 
 
 
        7. PREVALENCE OF HYPERURICEMIA 
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7. PREVALENCE OF HYPERURICEMIA  
 CASE CONTROL TOTAL 
 
 p value 
Hyperuricemia 22 4 26 0.000041 
(Significant) Normouricemia 28 46 74 
TOTAL 50 50 100 
 
 
          Table – 11 showing hyperuricemia distribution among study group and control 
group 
When comparing hyperuricemia between cases and controls it was found that 
there was a significant number of cases having hyperuricemia as compared to controls. 
Results analysed using chi square test showed a statistically significant ‘p’ 
value. 
 
 
 
 
 
  
 
 
 
8. SERUM CREATININE ANALYSIS 
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  8.  SERUM  CREATININE ANALYSIS 
 
Name of the 
substance 
CASE CONTROL  
p value 
Mean Standard 
Deviation 
Mean Standard 
Deviation 
 
CREATININE 
 mg/dl 
 
0.922  
 
0.16 
 
 0.798  
 
0.098 
 
<0.00001      
Significant 
 
 
Table -6 showing mean value of creatinine 
When comparing the serum creatinine level between cases and controls it was 
found that there was a significant increase in the creatinine value in the study group than 
in the control group. 
Results analysed using student ‘t’ test shows a statistically significant ‘p’ value. 
 
 
  
9. CORRELATION OF  THYROID PROFILE AND CREATININE IN  
HYPOTHYROIDISM 
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9. CORRELATION BETWEEN THYROID PROFILE AND SERUM 
CREATININE LEVELS IN HYPOTHYROID PATIENTS 
Thyroid 
hormones 
Serum Creatinine(mg/dl) 
‘r’ value  
 
       ‘p’  value 
T3(ng/ml) 0.0621   0.668 (Not Significant) 
T4 (µg/dL) - 0.0645   0.658  (Not Significant) 
TSH (µIU/ml) 0.1631  0.258 (Not Significant) 
 
Table -9 showing correlation between thyroid profile and creatinine in hypothyroid 
patients  
When correlating between thyroid profile (T3,T4,TSH) and serum creatinine in 
hypothyroid patients, the correlation between T4 and creatinine, correlation between T3 
and creatinine, TSH and creatinine were all weak and not statistically significant. 
Results were analysed using Pearson correlation coefficient test. 
 
 
 
  
 
 
 
                              10. e GFR DISTRIBUTION 
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       10. e GFR DISTRIBUTION 
 eGFR 
( ml/min/1.73m2) 
CASE CONTROL TOTAL 
 
>90 9 31 40 
60-89 34 19 53 
30-59 7 0 7 
TOTAL 50 50 100 
 
Table – 12 showing e GFR distribution among study group and control group 
 
When comparing e GFR values among cases and controls it was found that 
majority of cases have GFR value between (60-89 ml/min/1.73 m2) as compared to 
controls in whom majority of them have  their e GFR value above 90 ml/min/1.73 m2 and 
no controls having e GFR value below 60 ml/min/m2.  
 
 
 
 
  
 
 
                 
             11. MEAN VALUE OF e GFR 
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    11 .  MEAN VALUE OF e GFR 
 
 e GFR 
(MDRD 
equation) 
CASE CONTROL  
p value 
Mean Standard 
Deviation 
Mean Standard 
Deviation 
 e GFR 
 
ml/min/1.73m2 
 
78.83   
 
16.28 
 
93.62  
 
 
12.58 
 
<0.00001      
Significant 
 
 
Table -7 showing mean value of  e GFR 
When comparing the e GFR value calculated using MDRD equation between 
cases and controls it was found that there was a significant decrease in e GFR value in the 
study group than in the control group. 
Results analysed using student ‘t’ test disclosed a statistically significant ‘p’ 
value. 
 
 
 12 .CORRELATION OF  THYROID PROFILE AND e GFR  IN  
HYPOTHYROIDISM 
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 12.CORRELATION BETWEEN THYROID PROFILE AND e GFR IN 
HYPOTHYROID PATIENTS 
Thyroid 
hormones 
e GFR (ml/min/1.73m2) 
‘r’ value  
 
       ‘p’  value 
T3(ng/ml) -0.055  0.704 (Not Significant) 
T4 (µg/dL) 0.2096 0.144 (Not Significant) 
TSH (µIU/ml) -0.1543  0.285 (Not Significant) 
 
Table -10 showing correlation between thyroid profile and e GFR value in hypothyroid 
patients  
When correlating between thyroid profile (T3,T4,TSH) and e GFR value in hypothyroid 
patients, the correlation between T3 and e GFR, T4 and e GFR ,TSH and e GFR was 
weak and not statistically significant. Results were analysed using Pearson correlation 
coefficient test. 
 
 
 
 
 
         
 
 
 
 
 13. e GFR ANALYSIS 
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>90 ml/min/1.73 m2 <90 ml/min/1.73 m2
              13 . e GFR ANALYSIS 
 
eGFR 
( ml/min/1.73m2) 
CASE CONTROL TOTAL 
 
p value 
>90 9 31 40 0.000007 
(Significant)  <90 41 19 60 
TOTAL 50 50 100 
 
          Table – 13 showing e GFR Analysis among study group and control group 
When comparing e GFR between cases and controls it was found that there was a 
significant number of cases having e GFR values below 90 ml/min/1.73 m2 as compared 
to controls who have significant  number of people with e GFR above 90 ml/min/1.73 m2 
Results were analysed using chi square test which shows a statistically 
significant ‘p’ value. 
 
 
 
 
  
 
 
 
  DISCUSSION 
      DISCUSSION  
Present study evaluated the effect of hypothyroidism on parameters of renal 
function and to compare it with euthyroid subjects and also to study the correlation of 
(TSH, T4 and T3 ) with  uric acid, creatinine and e GFR . 
1.AGE: 
 Person with age group 21 – 45 years were included in this study. Mean age of this 
study and control group were 34.14 (years)  and 29.92 (years) respectively. Most of the 
people in study group belonged to the age group of 31 to 40 years and that of control 
group belonged to age group 21-30 years . 
In a study conducted by  Chandhury H.S. et al ., 2013, the most common age 
group 30-39 years. the mean age of hypothyroid and controls were nearly same.However, 
hypothyroidism was found more common in 25-35 years age group.  
 Another study done by Qahtan A. Rashead
 
 et al 2015 , the highest percentage 
of people were in age group 26-45 years. 
2.BODY MASS INDEX: 
 Mean BMI of the study and control group were 25.49(kg/m
2
)  and 25.32 (kg/m
2
) 
respectively. There is no significant difference between study and control group as 
contrast to Chandhury H.S. et al ., 2013 having significant difference in BMI between 
Hypothyroid group and euthyroid group. 
 3.GENDER: 
Among cases 5 were males and 45 were females and in healthy controls 4 were 
males and 46 were females. The percentage rate of females was more than the percentage 
rate of males .The results of this study were similar to Chandhury H.S. et al ., 2013 who 
recorded hypothyroidism was more frequent in females. 
Tejomani M et al 2013 also observed the prevalence of hypothyroidism was 
higher among females .The increased predisposition of females is observed in overt and 
subclinical hypothyroids. 
Also in Qahtan A. Rashead
 
 et al 2015 study- distribution of study population 
had more percentage rate of females than the percentage rate of males  
4.THYROID PROFILE AMONG STUDY AND CONTROL GROUP:                                  
 In this study, the mean value of T3 among study group and control group is 
0.854(ng/ml) and 1.5(ng/ml) respectively and that of  T4  among study group and control 
group is  6.42 (µg/dL) and 9.57 (µg/dL) respectively .It is seen that the  (T3 ,T4) level 
significantly decreased in study group when compared  to control the finding is very 
similar to Singh et al 2006, Nagarajappa et al 2014. 
In this study, mean TSH value among study group and control group is 
32.02(µIU/ml) and 2.25(µIU/ml) respectively. There is a significant difference in TSH 
value among study and control group which is very similar to study conducted by 
Vijayapriya I Indrajith 2016 which showed decreased level of T3 and T4 and increased 
TSH in the study when compared to that of control group. This is due to decreased 
 synthesis of thyroid hormones and loss of negative feedback control when compared to 
healthy individuals 
5.SERUM URIC ACID LEVELS: 
A) MEAN VALUE OF SERUM URIC ACID IN STUDY AND CONTROL GROUP 
The mean serum uric acid value of study and control group are 6.87 mg/dl and 
5.41 mg/dl respectively .When comparing the mean serum uric acid values between study 
and control it was high in study group as in control group and the difference is 
statistically highly significant. 
This is due to the effect of  hypothyroidism on renal physiology which leads 
decrease in renal plasma flow and impaired glomerular filtration and impaired urate 
excretion thereby increase in serum uric acid levels. 
 A study done by Devika Tayal et al 2009 showed an significant increase in 
serum uric acid levels in hypothyroid patients as compared to euthyroid subjects. In a 
case-control study done by Khan et al 2010  showed serum uric  acid  level  significantly 
higher in cases compared to controls 
Another study done by Sarika Arora et al 2009 showed that there is significant 
increase in  uric acid levels in hypothyroid patients as compared to euthyroid subjects. 
The changes in biochemical marker of renal function were found to be reversible after 
thyroxine replacement therapy. A study done by Ajaykumar et al 2013,also showed 
increase in uric acid levels in newly diagnosed hypothyroid patients ,which decreased 
 with 6 months of thyroxine replacement therapy. These studies suggest that increase in 
uric acid level is because of hypothyroid effect on kidneys leading to impaired urate 
excretion and once thyroxine supplementation is done it is reversible. 
Very similar results were found in subsequent studies like Nagarajappa et al 
2014 showed  increase in uric acid levels in cases as compared to controls and the 
increase is statistically highly significant, the hyperuricemia is secondary to decreased 
renal plasma flow and urate excretion.  
  Marwah et al 2015 stated that there study evaluated the possible interrelationship 
between purine nucleotide metabolism and primary hypothyroidism. Significant increase 
in uric acid levels was found in the patients with hypothyroidism and the hyperuricemia 
in hypothyroidism is associated with increased serum creatinine levels. This fact suggests 
that hypothyroid hyperuricemia is secondary to reduction in renal plasma flow and 
glomerular filtration. 
Gulab kanwar et al 2015, Gagandeep sidhu et al 2016, vijayapriya I Indrajith 
2016  these studies also  showed serum uric acid level was significantly increased in 
hypothyroid patients than controls and  hyperuricemia is secondary to a decreased renal 
plasma flow and impaired glomerular filtration. 
since 75% of uric acid is eliminated through kidneys, in patients with 
hypothyroidism impaired renal function is one of the etiology for hyperuricemia.  
 
 B)  CORRELATION BETWEEN THYROID PROFILE AND SERUM URIC ACID 
IN STUDY GROUP (HYPOTHYROID) 
In this study, uric acid showed negative correlation with T3 (-0.079) and T4 (-
0.3915), positive correlation with TSH (0.2505), but correlation with T4 is alone 
statistically significant and with T3, TSH were very weak.  
This finding indicates that uric acid levels are negatively regulated by thyroid 
hormones, especially T4 and they tend to increase in overt hypothyroid cases where T4 
levels are low. 
In Tayal et al 2009 study uric acid showed a significant negative correlation only 
with T3 levels in overt hypothyroid group and weak negative correlation with T4 and 
positive correlation with TSH. 
  In Sarika arora et al 2009 study  uric acid showed a significant negative 
correlation with T3 levels. Vaneet kaur et al 2015 found a negative correlation between 
T3,T4 and uric acid and a positive correlation between TSH and uric acid but they were 
not  statistically significant similar to this study. 
Lai -Chu See et al 2014 study there was no significant correlation between TSH and 
serum uric acid levels. In  Jia D et al 2015 study TSH showed no correlation with serum 
uric acid, Free T4 and Free T3 showed negative correlations with serum uric acid. 
Gulab Kanwar et al 2015 showed TSH is positively correlated with uric acid is 
statistically significant.  
 C) PREVALENCE OF HYPERURICEMIA AMONG STUDY GROUP AS 
COMPARED TO CONTROL GROUP 
In this study the prevalence of hyperuricemia is high among hypothyroid group 
than euthyroid control group.In study group it is 44% as compared to 8% in control 
group. The results are very similar to previous studies suggesting  hyperuricemia  
occurring more common in hypothyroidism and is due to impaired renal function. 
Erickson et al 1994  evaluated 54 patients with a documented gouty arthritis for 
the presence of hypothyroidism. The prevalence of hypothyroidism was significantly 
higher in patients with gouty arthritis. Overall, 15% of these patients, 25% of women and 
12% of men, had hypothyroidism. These rates were 2.5-fold greater in women and 
sixfold greater in men than found in the controls  
Study done by Giordano et al 2001 showed 33.3% prevalence of hyperuricemia 
in patients with hypothyroidism as compared to 10% prevalence in general population. 
Similar studies were conducted Dariyerli et al 2003 and found hyperuricemia in patients 
with hypothyroidism. There is high prevalence of hyperuricemia and gout in 
hypothyroidism. In hypothyroidism the hyperuricemia is secondary to a decreased renal 
plasma flow and impaired glomerular filtration 
Giordano et al 2001 found a significant increase in the incidence of both 
hyperuricaemia and gout in the hypothyroid patients. Hyperuricemia leading to gout had 
been reported in Hypothyroid subjects in a few studies done around the world. In present 
 study though showed high prevalence of hyperuricemia but there was no case of gout 
reported. This is similar to study done by  Tayal D et al 2009 which showed that no case 
of gout was reported despite the presence of Hyperuricemia in overtly hypothyroid cases. 
 6.SERUM CREATININE LEVELS: 
A) MEAN VALUE OF SERUM CREATININE IN STUDY AND CONTROL 
GROUP 
The mean serum creatinine value of study and control group are 0.922  mg/dl and 
0.798 mg/dl respectively .When comparing the mean serum creatinine values between 
study and control it was high in study group as in control group and the difference is 
statistically highly significant. 
This is due to the effect of hypothyroidism on renal physiology which leads 
decrease in renal plasma flow and impaired glomerular filtration and impaired creatinine 
excretion thereby increase in serum creatinine levels. 
Jayagopal et al. 2003 studied the effects of the hypothyroid state on changes in 
serum creatinine in 17 patients with hypothyroidism. All patients were newly diagnosed. 
The hypothyroid patients had a mean serum creatinine of 1.02mg/dl. It had been 
confirmed that the rise in creatinine levels in hypothyroid patients did not relate to 
abnormalities in other renal functions or creatine kinase levels suggesting that neither 
hypothyroid myopathy nor intrinsic renal disease contributed to the changes seen in 
creatinine levels 
  In Sukrella Khalid et al 2006 study, mean serum creatinine levels increased in 
hypothyroidism as compared  to the control group.Tayal et al 2009 found that mean 
serum creatinine concentrations were significantly increased in both patient groups i.e. 
sub-clinical and overt hypothyroid as compared to euthyroid subjects. 
Study conducted by Sinisa et al 2011, observed increase in serum creatinine in 
hypothyroid subjects which decreased after treatment. Decreased GFR , decreased 
creatinine clearance and decreased creatinine tubular secretion together with the increased 
release of creatinine from muscle cells explain the higher values of serum creatinine in 
hypothyroidism. 
Similar findings were seen in subsequent studies Chaudary et al 2013 ; Tejomani 
M et al  2013 ; Khan et al 2013 ; Nagarajappa et al 2014; Mamantha et al  2016. All 
these Studies say that the elevated serum creatinine levels in hypothyroid patients are due 
to physiological effects including alterations in renal hemodynamics, decrease in GFR 
and reduced clearance of creatinine. Some argue that serum creatinine level may also be 
increased due to hypothyroid myopathy. 
Sarika Arora et al  2009 The levels of serum creatinine in hypothyroid subjects 
were within normal range (< 1.4 mg/dl) but significantly  higher than in the euthyroid 
subjects (p<0.001). A significant decrease was observed in serum Creatinine, after 6 
weeks of thyroxine replacement therapy. After 6 weeks of thyroxine replacement, the 
value of creatintine was comparable to euthyroid group.A study done by Ajaykumar et 
al 2013 also showed increase in serum creatinine levels in newly diagnosed hypothyroid 
patients which decreased with 6 months of thyroxine replacement therapy  
 Thus the increase in creatinine in hypothyroid patients, though on the higher side 
of physiological range is high then the controls and is statistically significant and is 
mainly because of alterations in renal hemodynamics leading to decrease in GFR, 
reduced creatinine secretion, thus decreased creatinine excretion. 
B) CORRELATION BETWEEN THYROID PROFILE AND SERUM 
CREATININE IN STUDY GROUP 
In this study , serum creatinine has positive correlation with T3 (0.0621) and 
TSH(0.1631), negative correlation with T4(- 0.0645). But all were weak and statistically 
not significant. 
In Tayal et al 2009, there was significant negative correlation between serum 
creatinine and serum T3 & T4 levels and a significant positive correlation of serum 
creatinine with TSH levels.In Tejomani et al 2013, There was a significant negative 
correlation between T3 and creatinine and significant positive correlation between 
creatinine and TSH. In Chaudary et al 2013 TSH had positive significant correlation with 
serum creatinine. Mamantha et al  2016  shows significant positive correlation between 
TSH and serum creatinine levels  
 Jia D et al 2015 TSH showed weak negative correlation with creatinine, FT3 
and FT4 showed significant negative correlation with creatinine. Vaneet kaur et al 2015 
TSH showed a significant positive correlation with serum creatinine levels whereas fT4 
 and fT3 did not show any significant correlation with creatinine. This studies are showing 
mixed observations. 
Zahoor ahmed et al 2015 there is a positive relationship between thyroid 
stimulating hormone (TSH) and tri-iodothyronine (T3) with Creatinine whereas tetra-
iodothyronine (T4) showed a negative correlation very similar to this study. 
7. e GFR LEVELS: 
A) e GFR DISTRIBUTION AMONG STUDY VERSUS CONTROL GROUP 
When comparing e GFR between cases and controls it was found that there was a 
significant number of cases having e GFR values below 90 ml/min/1.73 m
2
 as compared 
to controls who have significant  number of people with e GFR above 90 ml/min/1.73 m
2
 
and no controls having e GFR value below 60 ml/min/m
2
 as compared to seven in cases. 
Thus showing that hypothyroidism has effect on renal physiology affecting the 
glomerular filtration rate. 
B) MEAN VALUE OF e GFR LEVELS IN STUDY AND CONTROL GROUP 
In this study the mean  e GFR values among study and control  78.83 ml/min/1.73 
m
2
 and 93.62 ml/min/1.73 m
2
 . The mean e GFR value is low in study group as compared 
to control group and the difference is statistically highly significant. 
This is due to the effect of  hypothyroidism on cardiovascular system leading to 
hypodynamic circulatory state thus reduced renal blood and plasma flow hence reduced 
GFR and apart from it because of reduction in Na+K+ ATPase expression thus reduction 
 in sodium reabsorption , there is altered response of   tubuloglomerular feedback leading 
to further reduction in GFR.  
Lippi G et al 2008 - indicated a mutual relationship between kidneys and thyroid 
status where TSH >2.5mIU/L were associated with decreased estimated glomerular 
filtration rate (e-GFR). 
 In Anne et al 2008  study , eGFR was calculated using the simplified 
Modification of Diet in Renal Disease Study equation and it was found that the mean e 
GFR value is low in hypothyroid as compared to euthyroid and  stated that in 
hypothyroidism, decreased eGFR probably reflects a true reduction in GFR. The 
mechanism of this is thought to be the decreased cardiac output caused by the reduced 
cardiac heart rate, stroke volume and contractibility all of which are caused by low 
thyroid hormone status.  Although there is an increased systemic vascular resistance, 
overall there is a decrease in systemic blood volume and consequently a reduction in 
GFR. . When a low eGFR is encountered, hypothyroidism should be considered as a 
possible cause 
   Kreisman SJ and  Hennessey  et al 1999 study showed that the reduced GFR 
seen in hypothyroidism is not associated with abnormal urinalysis, suggesting that the 
renal disease present is not intrinsic renal disease, but represents pre-renal disease as 
discussed above.  
 Sukrella Khalid et al 2006, In hypothyroid patients mean estimated GFR was 
decreased as compared to mean estimated GFR control group  and the difference is 
statistically significant. 
Tejomani et al 2013 eGFR was significantly decreased in overt cases as compared to 
subclinical cases and controls and are highly significant . This show a decline in renal 
function in overt hypothyroids 
 
C) CORRELATION BETWEEN THYROID PROFILE AND E GFR LEVELS IN 
STUDY GROUP 
In this study the e GFR value has negative correlation with T3(-0.055) and TSH    
(-0.1543) but positive correlation with T4 (0.2096). The correlation was weak and 
statistically not significant. 
In Tejomani et al 2013 there was positive correlation between e GFR and T3,T4 
and negative correlation between e GFR and TSH.  
 
 
 
  
 
 
 
CONCLUSION 
 CONCLUSION 
Present study shows that there is increased uric acid levels and creatinine levels 
and decreased e GFR levels in study group as compared to control group. The prevalence 
of hyperuricemia is high in hypothyroidism. These changes in the  biochemical values is 
because of the renal dysfunction evident by decrease in mean e GFR level as compared to 
mean e GFR level in control group. 
Thus these findings are helpful in understanding the interaction between thyroid 
gland and kidney showing the detrimental effect of hypothyroid state on renal 
functioning. This renal impairment is often overlooked but is readily reversible by 
prompt treatment leading to normalization of biochemical markers 
Hence it is suggested  
1. To assess the renal status of the patient at the time of diagnosis of  Hypothyroidism.  
2. To have strict observation of these parameters in follow up phase especially in person 
having risk factors for developing kidney disease eg-hypertension , diabetes mellitus 
3. To do Thyroid screening in person presenting with these biochemical abnormalities 
and patients  having worsening Chronic renal failure without any cause.  
 
 
 
LIMITATIONS:   
Further studies can be planned 
 with the larger sample size  
 multiple measurement of serum uric acid , serum creatinine,  TSH levels 
 To study the biochemical values in same patients after treatment      
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PROFORMA 
A STUDY OF SERUM URIC ACID LEVELS AND 
SERUM CREATININE LEVELS   IN HYPOTHYROIDISM 
PROFORMA 
Name:      Address: 
Age:        
Sex: M/F.     Occupation: 
 
COMPLAINTS    Y/N    DURATION 
H/O  weight gain 
H/O hair loss,dry skin 
H/O giddiness, palpitations 
H/O constipation 
H/O loss of appetite 
H/O  coldintolerence 
H/O lethargy 
H/O memory disturbances 
H/O tremors 
H/O myalgia 
H/O fatigue 
H/O neck swelling 
H/O menstrual disturbances 
 
Other symptoms: 
 
 
 
PAST HISTORY 
MEDICAL 
1.DiabetesMellitus , Hypertension 
2.CKD/ Renal disorders 
3.Gout / Muscular disorders 
4. CAD/Cardiovascular disorders 
5.Liver disorders 
6.H/O drug intake 
7. Malignancy 
8.Pregnancy/Lactation 
9. H/O surgery/allergy 
Any other condition 
 
PERSONAL HISTORY: 
Smoking-    Alcoholism- 
Diet- 
FAMILY HISTORY; 
Family history of renal disorders/CKD/Gout 
Muscular disorders/hypothyroidism 
MENSTRUAL HISTORY: 
 
 
 
OBSTETRIC HISTORY: 
 
 
 
GENERAL EXAMINATION 
Height ( cm)-     Pulse rate   -                             / min 
Weight( kg)-    Blood pressure   -                      mm.Hg 
BMI(kg/m
2 
)
 
 -    Respiratory rate     -                   / min. 
Anaemia-    Cyanosis-   
Clubbing-    Lymphadenopathy-   
Examination of neck - 
Cardio Vascular System- 
Respiratory System - 
Central nervous system- 
Abdomen- 
INVESTIGATIONS DONE- 
Thyroid profile- T3 
    T4 
  TSH 
Serum Uric acid- 
Serm creatinine- 
கேட஬ சு஭ப்பி குறமபாடு உள்ர க ா஬ாரிேரில் சீ஭ம் யூரிக் அ஫ியம் ஫ற்றும் சீ஭ம் 
ேிரிக஬ட்டினின் அரவு பற்மி ஆய்வு சசய்தல். 
மருத்துவ பரிச ோதனைமுனைகனை ப்பற்ைி மருத்துவரிடம் ததரிந்து தகோண்சடன் .  
இதனை சமற்தகோள்ை நோன் முழுமைதுடன்  ம்மதிக்கிசைன் .    
 
 
 
 
 
  
 
 
 
       MASTER CHART 
                                                                               GROUP I (CASE)– HYPOTHYRIOD STATE 
S.No                           Name  Age(in 
years)  
Sex   Ht 
(cm) 
Wt 
(kg) 
BMI(kg/m2
) 
PR(per 
min) 
BP(mm 
Hg) 
RR (per 
min) 
T3 
ng/ml 
T4 
µg/dL 
TSH 
µIU/ml 
Sr.Uric 
Acid 
mg/dl 
Sr.Creatinine 
mg/dl   
e GFR 
ml/min/1.73m2 
 
1 JAYANTHI 25 F 154 45 
18.97 
76 110/70 16 0.24 1.52 65 7.3 0.9 81.08 
2 RAKAYEE 44 F 158 58 23.23 72 120/80 18 0.69 8 30.8 8.4 1 64.02 
3 NAGAMMAL 40 F 172 65 21.97 73 110/80 19 1.2 3 45 9.2 1.1 58.47 
4 SHANTHI 28 F 162 68 
25.91 
69 100/70 22 0.85 7 15 6.2 0.8 90.78 
5 RAJESH 40 M 176 70 
22.59 
78 110/70 17 1.4 4.24 85 6.9 1.1 74.14 
6 PANDIAMMAL 40 F 150 76 
33.77 
80 120/80 18 0.33 7.78 42.51 6.2 0.9 73.71 
7 FATHIMA 44 F 148 76 34.69 68 100/70 17 0.66 0.66 18 7 1 64.02 
8 SUBRAMANI 44 M 164 70 26.02 72 110/70 19 0.76 11.5 24 6.9 1 81.17 
9 SELVI 30 F 146 50 
23.45 
74 120/80 17 0.9 3 43 7.6 0.8 89.51 
10 PADMA 34 F 152 55 
23.80 
72 100/70 18 0.24 7.78 31.6 6.5 0.8 87.27 
11 BINDOSE 35 F 148 65 29.67 68 110/80 18 0.69 3 38 7 0.9 75.73 
12 ANNALAKSHMI 30 F 155 70 29.13 69 110/70 19 1.2 8.63 14.67 6.8 0.9 78.14 
13 ISHWARYA 37 F 157 75 
30.42 
76 120/80 19 0.85 10.73 35.68 4.5 0.8 85.78 
14 ARUL ROJA 40 F 150 60 
26.66 
75 110/80 22 1.4 6.4 14.64 4.8 0.8 84.44 
15 KALEESHWARI 42 F 164 60 22.30 72 100/70 20 0.33 3 45 7.6 0.8 83.6 
16 MUTHUARASI 36 F 182 70 21.13 64 110/70 21 0.66 3.6 65 6.2 0.9 75.3 
17 MUTHULAKSHMI 33 F 160 60 
23.43 
68 120/80 20 0.4 3.5 40 7.5 0.8 87.8 
18 KOKILA 30 F 152 43 
18.61 
66 110/80 21 0.7 6.3 40 8.7 0.9 78.14 
19 SARANYA 25 F 168 60 21.25 69 110/70 20 0.95 10.1 25.6 4.5 0.7 108.37 
20 MURUGESHWARI 36 F 170 65 22.49 72 120/80 21 0.9 10 45 6.3 0.8 86.26 
21 SHALINI 28 F 165 55 
20.20 
76 120/80 16 0.9 11.2 17 4.2 0.6 115.2 
22 ANITHA 45 F 155 65 
27.05 
80 110/80 19 0.33 9.51 11.82 6.8 1.2 51.63 
23 PARAMESHWARI 30 F 156 60 
24.65 
84 120/80 18 0.85 1.6 53 5 0.9 78.14 
24 RAMLAKSHMI 35 F 146 55 25.80 77 110/70 16 0.2 3 39 9 1 67.06 
25 RAMESH 25 M 168 78 27.63 86 110/80 17 1.2 8 45 6.5 0.9 102.82 
 
                                                                               GROUP I (CASE)– HYPOTHYRIOD STATE 
S.No                           Name  Age(in 
years)  
Sex   Ht 
(cm) 
Wt 
(kg) 
BMI(kg/m2
) 
PR(per 
min) 
BP(mm 
Hg) 
RR (per 
min) 
T3 
ng/ml 
T4 
µg/dL 
TSH 
µIU/ml 
Sr.Uric 
Acid 
mg/dl 
Sr.Creatinine 
mg/dl   
e GFR 
ml/min/1.73m2 
 
26 JEYALAKSHMI 45 F 152 59 
25.5 
74 120/80 19 1.14 3.2 42 8.9 0.9 71.96 
27 RADHA 40 F 162 65 24.76 75 110/70 18 1.75 9.4 34.58 7.5 0.9 73.71 
28 KAVITHA 32 F 160 85 33.20 64 110/80 17 0.78 4.5 21 8.4 0.8 88.35 
29 ALAGAR 33 M 172 55 
18.59 
69 120/80 18 0.4 2.1 37 6.3 1 86.06 
30 LAKSHMI 42 F 164 60 
22.30 
72 120/80 19 0.24 1.47 16 7.9 0.7 97.53 
31 SABULLAH 39 M 182 72 
21.73 
78 110/70 18 0.69 12.61 14.21 7.6 0.7 118.2 
32 GAYATHRI 22 F 152 51 22.07 80 100/70 16 1.2 8.76 23.2 5.8 0.8 95.33 
33 YAGAPRIYA 26 F 140 60 30.61 82 110/80 15 0.85 5.91 17.34 6.7 0.7 107.51 
34 VELAKANNI 31 F 146 62 
29.08 
88 120/80         20 1.4 6.4 35 7.8 1.1 61.57 
35 SUDHANYA 33 F 158 65 
26.03 
80 110/80 21 0.33 11.24 30.4 7.1 1.2 54.99 
36 KALEESHWARI 22 F 162 60 22.86 74 120/80 22 0.66 8.4 40.6 7.3 1 73.69 
37 SUJITHA 22 F 160 70 27.34 76 110/80 20 0.9 13.37 12.48 5.4 0.8 95.33 
38 SINDHU 32 F 157 76 
30.83 
75 100/70 22 0.96 8.6 27.25 5.9 1.5 42.77 
39 GOWRI 22 F 155 40 
16.64 
73 110/80 19 0.99 5.07 29.72 6.5 1 73.69 
40 ANANDHI 33 F 165 55 20.20 74 120/80 18 1.1 6.2 15.62 6.8 1 67.87 
41 MURUGESHWARI 33 F 170 75 25.95 64 110/70 18 1.2 4.5 61.08 8.6 1.1 60.8 
42 SAROJA 43 F 172 80 
27.04 
69 110/80 18 0.75 5.47 10.36 6 1.1 57.62 
43 ANBHU 38 F 160 85 
33.20 
85 110/70 17 0.62 7.38 19.38 7.2 1.1 59.08 
44 FATHIMA 21 F 154 80 33.7 80 120/80 17 0.85 6.36 10.5 6.6 0.9 84.01 
45 USHARANI 40 F 150 64 28.44 78 100/70 18 0.99 5.6 47.2 8.3 1.1 58.47 
46 LAKSHMI 35 F 148 60 
27.39 
74 110/70 19 1.2 4.7 47.65 7 0.9 75.73 
47 CHITRA 45 F 157 55 
22.31 
72 120/80 19 1.8 7.92 10.22 7.2 1 63.73 
48 ANDAL 35 F 160 70 
27.34 
70 110/70 19 1.1 5.4 18 6.7 0.9 75.73 
49 VASANTHI 31 F 162 75 28.57 76 100/70 19 1.02 5.98 35.1 6.6 0.8 88.92 
50 VIDHYA 36 F 174 73 24.11 74 100/70 20 0.95 7.4 15.8 6.1 0.8 86.26 
 
                                                                              GROUP II (CONTROL)– EUTHYRIOD STATE 
 
S.No                           Name  Age(in 
years)  
Sex   Ht 
(cm) 
Wt 
(kg) 
BMI(kg/m2
) 
PR(per 
min) 
BP(mm 
Hg) 
RR (per 
min) 
T3 
ng/ml 
T4 
µg/dL 
TSH 
µIU/ml 
Sr.Uric 
Acid 
mg/dl 
Sr.Creatinine 
mg/dl   
e GFR 
ml/min/1.73m2 
 
1 KARTIKA DEVI 27 F 
162 
58 22.1 80 110/80 19 1.24 9.92 1.75 3.4 0.7 106.69 
2 PODUMPONNU 33 F 155 62 25.80 72 110/70 18 0.89 11.15 3.02 5 0.8 87.8 
3 ARIVUKARASI 21 F 157 67 27.18 73 120/80 20 0.99 9.43 3.06 5.2 0.8 96.24 
4 VIJAYALAKSHMI 27 F 
146 
58 27.20 74 110/80 19 1.2 8.05 4.46 6.6 0.7 106.69 
5 SIVASELVI 24 F 
152 
62 26.83 85 110/70 20 1.6 10.3 1.05 5 0.8 93.66 
6 PANJAVARNAM 35 F 
162 
70 26.67 79 120/80 18 1.4 10.3 4.18 7 0.9 75.73 
7 KEERTHIGA 24 F 170 55 19.03 82 110/70 21 0.9 11 2.86 6 0.7 109.27 
8 KAVITHA 33 F 174 62 20.47 90 120/80 19 1.9 11.09 1.52 7.2 0.7 102.43 
9 MALA 25 F 
155 
50 20.81 77 110/80 20 2 10.99 1.27 6 0.7 108.37 
10 MUTHUKANNU 24 F 
165 
64 23.50 75 100/70 18 0.99 10.24 1.9 4.7 0.9 81.76 
11 ANITHA 25 F 145 55 26.15 85 110/70 16 1.24 10.96 3.38 6.8 0.7 108.37 
12 TAMIL SELVI 42 F 155 70 29.13 78 110/70 14 1.5 8.8 2.35 2.7 0.7 97.53 
13 SUDHA 21 F 
140 
60 30.61 76 100/70 19 1.75 8.6 2.88 6.5 1 74.39 
14 VIJAYALAKSHMI 45 F 
143 
50 24.45 75 120/80 17 1.62 4.09 3.3 7 0.8 82.44 
15 MUTHU 28 M 170 64 22.14 74 110/80 17 1.32 7.71 1.1 5.5 0.8 115.11 
16 KRITHIKA 26 F 158 50 20.02 77 110/70 17 1.45 8.9 2.61 3.1 0.8 92.15 
17 BALASUBRAMANI 43 M 
168 
72 25.51 78 120/80 20 2.05 9.68 4.43 5.5 1 81.55 
18 SUMATHI 21 F 
152 
60 25.96 77 100/70 22 1.96 10.68 1.58 5.3 0.8 96.24 
19 RAJAMMAL 25 F 154 64 26.9 86 110/70 15 1.5 7.29 1.72 6.4 0.7 108.37 
20 KAYALVIZHI 34 F 158 54 21.63 74 120/80 19 1.75 9.66 3.78 6 0.8 87.27 
21 SELVI 31 F 
142 
75 37.1 72 110/80 17 1.82 10.43 2.36 5.6 0.9 77.62 
22 PECHIAPPAN 43 M 
155 
73 30.38 74 100/70 18 2.1 8.43 4.78 6.4 0.8 105.51 
23 VINODHINI 23 F 
146 
55 25.80 78 110/70 20 1.99 8.37 1.56 5.8 0.7 110.22 
24 MUTHUMEENA 40 F 156 60 24.65 79 120/80 22 0.99 7.48 1.38 5.3 0.7 98.5 
25 NEELA 21 F 160 80 31.25 82 110/80 20 1.24 12.46 1.17 6.5 0.8 96.24 
 
                                                                              GROUP II (CONTROL)– EUTHYRIOD STATE 
 
S.No                           Name  Age(in 
years)  
Sex   Ht 
(cm) 
Wt 
(kg) 
BMI(kg/
m2) 
PR(per 
min) 
BP(mm 
Hg) 
RR (per 
min) 
T3 
ng/ml 
T4 
µg/dL 
TSH 
µIU/ml 
Sr.Uric 
Acid 
mg/dl 
Sr.Creatinine 
mg/dl   
e GFR 
ml/min/1.73m2 
 
26 MUTHARASI 29 F 162 65 
24.76 
67 110/80 16 1.5 9.12 1.57 5.6 0.8 90.13 
27 ABHINEKHA 26 F 157 52 21.09 80 100/70 18 1.75 7.27 1.98 4.9 0.7 107.51 
28 REKHA 37 F 154 52 21.92 72 120/80 19 1.62 6.8 2.02 5 0.8 85.78 
29 SELVARAJ 42 M 182 75 
22.64 
76 110/80 17 1.32 9.4 3.35 6.9 1.1 73.41 
30 PARIMALA 42 F 159 82 
32.43 
69 100/70 16 1.45 8.4 2.35 7.2 0.9 72.98 
31 JAYALAKSHMI 23 F 162 55 
20.95 
78 110/70 19 2.05 10.82 1.35 5.3 0.8 94.48 
32 SANKARI 35 F 174 65 21.46 79 110/80 20 1.96 12.22 1.89 5.2 0.8 86.76 
33 THAVASHREE 22 F 161 70 27.0 80 100/70 21 1.5 12.66 1.39 5.3 0.8 95.33 
34 THARINI 25 F 158 50 
20.02 
81 120/80 22 1.75 9.84 2.24 4.7 0.7 108.37 
35 ALAGUCHITRA 23 F 154 48 
20.2 
90 110/70 22 0.99 8.6 1.36 5.5 0.7 110.22 
36 ANDAL 42 F 150 65 28.88 82 110/80 16 1.2 11.29 2.9 5.8 0.8 83.6 
37 JEYA 34 F 148 62 28.30 72 100/70 18 1.6 9.6 0.56 6.1 1 67.46 
38 REHAMATH 31 F 152 65 
28.13 
69 120/80 17 1.4 6.23 1.67 5.9 0.9 78.14 
39 GEETHA 23 F 158 70 
28.04 
72 120/80 19 0.9 8.69 4.37 5.8 0.9 82.47 
40 SARANYA 25 F 162 76 28.9 68 100/70 18 1.9 7.8 1.28 5.4 0.8 92.89 
41 VASUGI 27 F 168 65 23.03 74 120/80 17 1.66 13.07 2.66 6.2 0.8 91.45 
42 RAJESHWARI 44 F 172 82 
27.71 
75 110/80 16 1.2 9.53 2.57 5.4 0.8 82.82 
43 NANDINI 24 F 156 54 
22.18 
71 120/80 18 0.99 12.76 1.68 4.3 0.7 109.27 
44 ANITHA 26 F 174 70 23.12 82 110/70 19 1.24 10.76 1.03 4.2 0.8 92.15 
45 SANTHANAM 28 F 170 65 22.49 78 100/70 19 1.5 12.52 1.74 5.3 0.8 90.78 
46 NANDINI 21 F 148 56 
25.56 
76 110/80 19 1.75 9.13 1.37 3.7 0.8 97.19 
47 KALA 29 F 152 70 
30.29 
80 110/80 20 1.62 8.07 2.87 4.7 0.9 78.68 
48 KALPANA 35 F 156 65 
26.70 
82 120/80 20 1.32 11.38 2.37 4.1 0.6 115.92 
49          VEERALAKSHMI 33 F 160 60 23.43 68 100/70 21 1.45 8.87 1.43 3.6 0.8 87.8 
50 NAGALAKSHMI 29 F 148 56 25.56 70 110/80 16 2.05 7.89 1.17 4 0.7 105.15 
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